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ABSTRACT 
Diabetic Ketoacidosis (DKA) is associated with pediatric cerebrovascular-related 
complications. DKA-associated inflammation instigates leukocyte adherence to the brain 
microvascular endothelium. As adhered leukocytes release enzymes that compromise 
vascular integrity, we questioned a role for leukocyte-derived matrix metalloproteinases 
(MMPs) and azurophilic enzymes (elastase, proteinase-3, myeloperoxidase). Our aims 
were to measure leukocyte-derived enzymes in DKA plasma, determine associations with 
DKA severity and investigate their effect on the cerebrovascular endothelium. 
Plasma was obtained from children with type-1 diabetes, either in acute DKA or 
insulin-controlled. DKA was associated with altered plasma levels of ↓MMP-2, ↑MMP-
8, ↑MMP-9 and ↑TIMP-4, which are largely leukocyte in origin. DKA was also 
associated with elevated plasma leukocyte elastase, proteinase-3 and myeloperoxidase. 
MMP-8, MMP-9 and proteinase-3 were positively correlated with DKA severity. 
Azurophilic enzymes decreased ZO-1 and degraded β-catenin in cerebrovascular 
endothelium. 
In summary, DKA is associated with dynamic regulation of leukocyte proteolytic 
enzymes that can impair blood brain barrier integrity.  
 
 
Key words: Human, Pediatric, Plasma, Diabetic ketoacidosis, Matrix metalloproteinase, 
Tissue inhibitor of metalloproteinase, Leukocyte, Elastase, Proteinase-3, 
Myeloperoxidase, β-catenin, ZO-1, Cerebrovascular endothelial cells. 
 iii 
 
CO-AUTHORSHIP STATEMENT 
Dr. G Cepinskas and Dr. DD Fraser provided valuable guidance in designing the 
experimental approach and interpreting the data collected in this study. The primary 
human brain microvascular endothelial cells were provided by Dr. M Bani (NRC, 
Ottawa).  
All text and figures in Chapter 1 were generated by M Woo.  
Chapter 2 is adapted from M Woo, Dr. EK Patterson, Dr. G Cepinskas, Dr. C 
Clarson, Dr. T Omatsu and Dr. DD Fraser. (2015). Dynamic regulation of plasma matrix 
metalloproteinases in human diabetic ketoacidosis. Ped Res. [submitted]. Figures and 
texts were generated by M Woo unless otherwise specified, and then reviewed by Dr. DD 
Fraser and Dr. G Cepinskas. Dr. EK Patterson generated Figure 2-3 and the qPCR 
methodology text.  
All texts and figures in Chapter 3 and Chapter 4 were generated by M Woo.  
 iv 
 
ACKNOWLEDGEMENTS 
I would like to give my thanks to my two wonderful supervisors, Dr. Fraser and 
Dr. Cepinskas for all the support and guidance they gave me as I completed my graduate 
degree. I would like to thank my advisory committee, Dr. Donglin Bai and Dr. Tianqing 
Peng for their helpful guidance regarding my research. Thanks to Dr. Carolina Gillio-
Meina for assistance with the TRC plasma samples. Thank you to my labmates, Dr. Ken 
Inoue and Dr. Eric Patterson for the help gave me. Lastly, I would like to thank Sam 
Medwid for all the encouragement and moral support she has given me over the past 2 
years. 
  
 v 
 
TABLE OF CONTENTS 
ABSTRACT ..................................................................................................................................... ii 
CO-AUTHORSHIP STATEMENT ................................................................................................ iii 
ACKNOWLEDGEMENTS ............................................................................................................ iv 
LIST OF TABLES ........................................................................................................................ viii 
LIST OF FIGURES ........................................................................................................................ ix 
LIST OF APPENDICES .................................................................................................................. x 
LIST OF ABBREVIATIONS ......................................................................................................... xi 
CHAPTER 1: INTRODUCTION .................................................................................................... 1 
1.1 Type 1 Diabetes Mellitus ....................................................................................................... 2 
1.2 Diabetic Ketoacidosis ............................................................................................................ 3 
1.3 DKA Cerebral Edema ............................................................................................................ 4 
1.4 Blood-Brain Barrier ............................................................................................................. 10 
1.5 Cerebrovascular Endothelial Cells ....................................................................................... 14 
1.6 Matrix Metalloproteinases ................................................................................................... 17 
1.7 Polymorphonuclear Neutrophils .......................................................................................... 24 
1.8 PMN Serine Proteases .......................................................................................................... 28 
1.9 Rationale .............................................................................................................................. 31 
1.10 Hypothesis ......................................................................................................................... 34 
1.11 Objectives .......................................................................................................................... 34 
1.12 References .......................................................................................................................... 35 
 vi 
 
CHAPTER 2: DYNAMIC REGULATION OF PLASMA MATRIX METALLOPROTEINASES 
IN HUMAN DIABETIC KETOACIDOSIS.................................................................................. 49 
2.1 Introduction .......................................................................................................................... 50 
2.2 Methods ............................................................................................................................... 51 
2.2.1 Human Subjects ............................................................................................................ 51 
2.2.2 Blood Collection and Processing .................................................................................. 51 
2.2.3 MMP/TIMP Antibody Microarray ................................................................................ 52 
2.2.4 MMP Gelatin Zymography ........................................................................................... 52 
2.2.5 Quantitative Real-Time PCR ........................................................................................ 54 
2.2.6 Statistical Analysis ........................................................................................................ 54 
2.3 Results .................................................................................................................................. 56 
2.4 Discussion ............................................................................................................................ 64 
2.5 Acknowledgements .............................................................................................................. 68 
2.6 References ............................................................................................................................ 69 
CHAPTER 3: ELEVATED LEUKOCYTE AZUROPHILIC ENZYMES IN HUMAN 
DIABETIC KETOACIDOSIS PLASMA DEGRADE CEREBROVASCULAR ENDOTHELIAL 
JUNCTIONAL PROTEINS ........................................................................................................... 73 
3.1 Introduction .......................................................................................................................... 74 
3.2 Methods ............................................................................................................................... 75 
3.2.1 Human Subjects ............................................................................................................ 75 
3.2.2 Blood Collection and Processing .................................................................................. 75 
 vii 
 
3.2.3 Polymorphonuclear Neutrophil Enzyme Measurement ................................................ 76 
3.2.4 Cell Culture ................................................................................................................... 76 
3.2.5 In vitro Experimental Approach ................................................................................... 76 
3.2.6 Immunoblotting ............................................................................................................. 77 
3.2.7 Quantification of Monolayer Detachment .................................................................... 78 
3.2.8 Statistical Analysis ........................................................................................................ 78 
3.3 Results .................................................................................................................................. 79 
3.4 Discussion ............................................................................................................................ 88 
3.5 References ............................................................................................................................ 93 
CHAPTER 4: DISCUSSION ......................................................................................................... 97 
4.1 Discussion ............................................................................................................................ 98 
4.2 References .......................................................................................................................... 102 
APPENDIX A .............................................................................................................................. 104 
VITA ............................................................................................................................................ 108 
 
 
 
 
 
 
 viii 
 
LIST OF TABLES 
TABLE 2-1. Clinical Data and Plasma MMP/TIMP Levels in Type-1 Diabetes Patients. ........... 57 
TABLE 3-1. Human Clinical and Biochemical Data for Type-1 Diabetes Patients ...................... 80 
TABLE 3-2. Differential White Blood Cell Count for DKA Patients ........................................... 81 
 
  
 ix 
 
LIST OF FIGURES 
FIGURE 1-1. Schematic Diagram of the Blood-Brain Barrier. ..................................................... 13 
FIGURE 1-2. Schematic Diagram of the CVEC Junctional Complexes. ...................................... 16 
FIGURE 1-3. Schematic Diagram of the Common Different Functional Domains of the MMP 
Family. ........................................................................................................................................... 22 
FIGURE 1-4. Schematic Diagram of the Classic Activation of MMPs......................................... 23 
FIGURE 1-5. Diagram of PMN Activation and Recruitment to the Vascular Endothelium. ........ 27 
FIGURE 2-1. Gelatin Zymography of DKA Plasma. .................................................................... 59 
FIGURE 2-2. Plasma MMP Correlation with pH in DKA. ........................................................... 61 
FIGURE 2-3. Leukocyte MMP Gene Expression in DKA. ........................................................... 63 
FIGURE 3-1. Plasma Leukocyte Azurophilic Enzymes in DKA. ................................................. 83 
FIGURE 3-2. Plasma PMN Azurophilic Enzyme Correlation with pH in DKA. .......................... 85 
FIGURE 3-3. Enzyme-Mediated Degradation of ZO-1 and β-Catenin. ........................................ 87 
FIGURE 4-1. Proposed Mechanism of PMN-mediated DKA Endothelial Perturbations. .......... 101 
 
  
 x 
 
LIST OF APPENDICES 
APPENDIX A .............................................................................................................................. 104 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 xi 
 
LIST OF ABBREVIATIONS 
ADC 
AJ 
ANOVA 
AP-1 
BBB 
BCA 
bFGF 
BUN 
CD 
CT 
CTLA 
CTSG 
CVEC 
CXCL 
DKA 
Apparent diffusion coefficient 
Adherens junctions 
Analysis of Variance 
Activating protein-1 
Blood-Brain Barrier 
Bicinchoninic acid 
Basic fibroblast growth factor 
Blood urea nitrogen 
Cluster of differentiation 
Computerized tomography 
Cytotoxic T-lymphocyte-associated protein 
Cathepsin G 
Cerebrovascular endothelial cell 
C-X-C motif ligand 
Diabetic ketoacidosis 
 xii 
 
DKA-CE 
ECM 
EDTA 
EGF 
ELISA 
ET-1 
ETV-4 
FBS 
FGF 
GM-CSF 
HbA1c 
hBMEC 
HIF 
HLE 
ICAM 
IFN 
IgG 
Diabetic ketoacidosis-cerebral edema 
Extracellular matrix 
Ethylenediaminetetraacetic acid 
Epidermal growth factor 
Enzyme-linked immunosorbent assay 
Endothelin-1 
E26 transformation-specific translocation variant 4 
Fetal bovine serum 
Fibroblast growth factor 
Granulocyte monocyte- colony stimulating factor 
Hemoglobin A1c 
Human brain microvascular endothelial cells 
Hypoxia-inducible factor 
Human leukocyte elastase 
Intercellular adhesion molecule 
Interferon 
Immunoglobulin 
 xiii 
 
IL 
JAM 
LFA 
MAC 
MCP 
MMP 
MPO 
MRI 
mRNA 
MT 
NF-κB 
NSP 
OD 
PAGE 
PECAM 
PMN 
PR-3 
Interleukin 
Junctional adhesion molecule 
Lymphocyte function-associated antigen 
Macrophage-associated protein 
Monocyte chemoattractant protein 
Matrix metalloproteinase 
Myeloperoxidase 
Magnetic resonance imaging 
Messenger ribonucleic acid 
Membrane-type 
Nuclear factor- κB 
Polymorphonuclear neutrophil serine protease 
Optical Density 
Polyacrylamide gel electrophoresis 
Platelet endothelial cell adhesion molecule 
Polymorphonuclear neutrophil 
Proteinase-3 
 xiv 
 
 
 
 
SD 
SDS 
SEM 
T1DM 
TGF 
TIMP 
TJ 
TNF 
uPA 
VCAM 
VEGF 
VL 
VNTR 
WBC 
ZO 
Standard deviation 
Sodium dodecyl sulphate 
Standard error of the mean 
Type 1 diabetes mellitus 
Transforming growth factor 
Tissue inhibitor of metalloproteinase 
Tight junction 
Tumor necrosis factor 
Urokinase plasminogen activator 
Vascular cell adhesion molecule 
Vascular endothelial growth factor 
Vasculife media 
Variable number tandem repeat 
White blood cell 
Zonula occludens protein 
1 
 
 
 
CHAPTER 1: INTRODUCTION 
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1.1 Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus (T1DM) is a serious affliction that persists throughout life 
(4). Globally, the incidence of T1DM varies greatly, anywhere from 0.5-30.3/100 000 
people per year with significant ethnic diversity (5). T1DM occurs predominantly in 
children younger than 15-18 years of age and in the past few decades, its incidence has 
been increasing (5, 6). Among juveniles with diabetes mellitus, T1DM accounts for over 
90% of the cases (7). Cases of T1DM account for 5-10% of all diabetics (4). 
Approximately 14.9 billion dollars is expended on T1DM annually, thus treatment and 
management of T1DM is of great significance to patients, healthcare professionals and 
researchers globally (8). 
T1DM is a condition caused by the destruction of the β-cells of the islets of 
Langerhans in the pancreas. These cells are responsible for all insulin production in the 
body and their destruction leads to an insulin deficiency. A lack of insulin results in an 
inability to regulate blood glucose effectively, leading to chronic hyperglycemia. T1DM 
is generally classified into 2 categories: Type 1A is the result of an autoimmune response 
destroying the β-cells whereas Type 1B is idiopathic destruction of the β-cells (4). Type 
1A diabetes mellitus has a predominantly genetic origin where polymorphisms in genes 
residing in the human leukocyte antigen (HLA) loci, the insulin-variable number tandem 
repeat (VNTR) and cytotoxic T-lymphocyte-associated protein (CTLA)-4 genes can 
confer susceptibility to T1DM (9, 10). The other facet of T1DM susceptibility involves 
environmental triggers that initiate the immune-mediated destruction of the β-cells in 
those already predisposed to it. Examples of triggers include viruses such as rubella, 
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environmental toxins such as N-nitroso compounds and food components such as cow’s 
milk proteins (11, 12).  
Symptoms of T1DM include polydipsia, polyphagia, weight loss, blurred vision, 
polyuria with glycosuria and fatigue. The symptoms of T1DM start to present themselves 
after approximately 90% of the β-cells have been destroyed (7). Therefore, by the time it 
is detected by clinicians, patients are already suffering from a severe insulin deficiency. 
Complications that can arise from uncontrolled blood glucose in T1DM are hypokalemia, 
hypophosphatemia, hypoglycemia, peripheral venous thrombosis, mucormycosis, 
rhabdomylosis, acute pancreatitis, acute renal failure, sepsis and aspiration pneumonia 
(13). Longer term complications include retinopathy, nephropathy, neuropathy, 
cardiovascular disease, cognitive impairment and increased susceptibility to certain 
infections (14). The most severe acute complication of T1DM is diabetic ketoacidosis 
(DKA). 
1.2 Diabetic Ketoacidosis 
DKA involves the breakdown and metabolism of fatty acids and amino acids for 
energy. It is caused by a severe deficiency in insulin together with altered levels of 
counterregulatory hormones such as catecholamines, glucagon, cortisol and growth 
hormones. Increased glycogenolysis and gluconeogenesis along with impaired glucose 
uptake by peripheral tissues results in a hyperglycemic and hyperosmolar state (15, 16). 
Increased serum glucose levels, beyond that which renal excretion is able to rectify, 
causes osmotic diuresis and depletion of electrolytes, leading to potentially fatal 
dehydration (15). Occurring concurrently is the metabolism of fatty acids in the liver to 
the ketone bodies, β-hydroxybutyrate and acetoacetate, which accumulate in peripheral 
4 
 
 
 
circulation, overwhelming the bicarbonate buffering system and contributing to metabolic 
acidosis. Clinically, DKA manifests with dehydration, Kussmaul respiration, nausea, 
vomiting, acute abdominal pain and reduced or loss of consciousness (15). Children who 
develop DKA possess a higher risk for intracranial vascular complications such as 
cerebral edema (17), hemorrhage (18) and stroke (19). 
The biochemical criteria for DKA involves hyperglycemia (blood glucose > 11 
mmol/L), venous pH < 7.3 or bicarbonate < 15 mmol/L and ketonemia or ketonuria (15). 
DKA is classified according to the severity of acidosis: Mild DKA is distinguished by a 
pH < 7.3, moderate DKA is distinguished by pH < 7.2 and severe DKA is distinguished 
by pH < 7.1 (20). 
DKA often occurs in “first time” diabetics, in undiagnosed and therefore, untreated 
T1DM cases. Other common events that precipitate DKA are the accidental or deliberate 
stoppage of insulin treatment (i.e., weight control in adolescents). Risk factors for DKA 
are extremely variable, including children with poor metabolic control, peripubescent 
females, children from troubled households and children with psychiatric disorders (21). 
1.3 DKA Cerebral Edema 
DKA, though a previously highly lethal condition, following the advent of insulin, 
has become much more manageable with a mortality rate below 2% (16). However, DKA 
still retains significant mortality due to related complications, one of which is cerebral 
edema (DKA-CE). DKA-CE is a serious and highly lethal condition, despite advances in 
management techniques. In North America, the incidence of DKA-CE among DKA cases 
is 0.5-0.9% with a devastating mortality rate of 21-24% (17, 22, 23). Some studies have 
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even reported a mortality rate of up to 90% (24). DKA-CE is the leading cause of death 
in pediatric cases of T1DM and leaves 30-40% of survivors with significant neurological 
damage (25). It has been surmised that DKA-CE mortality accounts for 80% of all 
diabetes-related deaths among children under 12 year of age (24). Ninety-five percent of 
DKA-CE patients are under 20 years of age and 33% are under 5 years of age (25). As 
such, DKA-CE is considered mainly a pediatric pathology. The reason for the apparent 
predisposition in children to this complication is not yet clear.  
Cases of DKA-CE usually occur within 2-24 hours after the onset of DKA 
treatment. Patients present with a sudden headache and reduced level of consciousness 
followed by rapid neurological degeneration and eventual herniation of the brain stem 
(13, 26). Thus, many researchers suspect DKA-CE to be a side effect of the interventions 
traditionally administered for DKA. However, it should be noted that cases of DKA-CE 
have been reported before the initiation of treatment (17, 22). Therefore, the etiology of 
DKA is more complex than just an adverse response to treatment. DKA-CE can manifest 
itself in two ways: from admission, the patient’s condition will steadily deteriorate into a 
comatose state or, more frequently, the patient will appear to recover and then suddenly 
worsen (24, 27).  
Much discussion has centered over the distinction between subclinical and 
symptomatic cerebral edema. In a study done on 6 children between the ages of 11 and 
14 years old with DKA who were asymptomatic for DKA-CE, it was discovered that all 6 
showed evidence of cerebral swelling via computerized tomography (CT) scans taken at 
the onset of treatment and at hospital discharge (28). Additionally, another study using 
brain encephalography detected the presence of significant cerebral swelling in 81% of 
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patients between the ages of 13-42 years old undergoing treatment for DKA, despite the 
absence of symptomatic cerebral edema (29). Taken together, these studies suggest that 
DKA-CE is far more common in pediatric cases of DKA than previously suspected. 
Conversely, another study evaluated ventricle size via CT following DKA treatment in 
patients 4-15 years old and found that subclinical DKA-CE did not occur frequently (30). 
These controversial findings may be explained by DKA-CE possessing a spectrum of 
severities from mild subclinical DKA-CE to severe symptomatic DKA-CE (31). 
Cerebral edema can be classified into 2 main categories: vasogenic edema and 
cytotoxic edema. Vasogenic edema is the flow of water into the extracellular space due to 
destabilization of the Blood-Brain Barrier (BBB). Cytotoxic edema is the flow of water 
into the intracellular space resulting in cell swelling (32). Though both cytotoxic and 
vasogenic edema are observed in pathological conditions, it has been suggested that the 
primary form of edema present in DKA, prior to treatment is that of the vasogenic type. 
Diffusion-weighted magnetic resonance imaging (MRI) of pediatric cases of DKA 
showed elevated brain apparent diffusion coefficient (ADC), indicating vasogenic edema 
(33, 34).  
 The exact cause of DKA-CE is still largely unknown at this point, though theories 
that have been proposed include increases in BBB permeability, increases in hydrostatic 
pressure due to aggressive fluid resuscitation concomitantly with decreased osmotic 
pressure, loss of cerebral autoregulation, osmotic disequilibrium from accumulation of 
intracellular osmoles in the brain, hypoxia and ischemia and intracranial acidosis (35).  
7 
 
 
 
A suggested mechanism of DKA-CE and perhaps the most convincing is the 
initiation of a pro-inflammatory cytokine cascade that results in BBB dysfunction. 
Observed consistently in DKA is an inflammatory cascade similar to that of systemic 
inflammatory response syndrome (36). This inflammatory cascade may trigger transient 
opening of the BBB. DKA has been shown to initiate a widespread inflammatory cascade 
involving the cytokines, C-X-C motif ligand (CXCL)-1, CXCL-8 and interferon (IFN)-α2 
(37). The same study also showed increased adherence of polymorphonuclear neutrophils 
(PMN) to the endothelium, providing convincing evidence of leukocyte involvement. 
Also reported to be upregulated in patients suffering from DKA are interleukin (IL)-1β, 
IL-6, IL-2 and tumor necrosis factor (TNF)-α, whose increase correlates with the 
timeframe of the development of subclinical DKA-CE (38). An immunological response 
during DKA is further supported by the detection of elevated levels of components of the 
complement pathway (C3a, Bb and C5b-9) (39) as well as C-reactive protein (CRP) (40). 
In juvenile mice, DKA increased circulating levels of numerous endothelial-specific 
molecules such as E-selectin, intracellular adhesion molecule (ICAM)-1 and vascular cell 
adhesion protein (VCAM)-1, indicating an onset of systemic inflammation (41). Thus, 
the onset of DKA involves a significant activation of the inflammatory cascade. It is well 
established that cytokines and the inflammation cascade lead to activation of the BBB 
endothelium as well as leukocytes and subsequent BBB disruption, resulting in increased 
water flux into the brain, hence the prevalence of cerebral edema in DKA (42-45). 
Furthermore, it is believed that acidosis per se plays an important role in DKA-CE. 
The ketone bodies, acetoacetate and β-hydroxybutrate are known to be pro-inflammatory 
agents that activate the endothelial cells in the BBB by increasing endothelin (ET)-1 and 
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vascular endothelial growth factor (VEGF) secretion (46). Both VEGF and ET-1 are 
known as vascular permeability inducing factors. In another study, acetoacetate was 
shown to increase expression of ICAM-1, a receptor that mediates leukocyte adhesion to 
the endothelium (47). Thus, ketone bodies are able to trigger inflammatory processes at 
the BBB endothelium and lead to the release of permeability inducing factors.  
Hyperglycemia, present during precipitation of DKA can initiate an inflammatory 
response as well. Hyperglycemic crises were associated with increased levels of 
circulating CRP, free fatty acids, CXCL-8, IL-6, IL-1β and TNF-α (48). Hyperglycemic 
conditions can also facilitate the activation of human T-lymphocytes, thus providing a 
mechanism by which hyperglycemia is able to trigger inflammation (49). Therefore, not 
only DKA, but also hyperglycemia per se is able to trigger an inflammatory response in 
the body by facilitating the production and release of circulating cytokines. The 
activation of the BBB endothelium by many of these cytokines leads to an increase in 
permeability of the BBB.  
Some studies have also addressed the role of hypoxia and ischemia in the 
development of DKA-CE. Factors like increased blood urea nitrogen (BUN) levels (17), 
and lower pCO2 levels (22) have been frequently associated with the development of 
DKA-CE. Studies have also shown that cerebral blood flow is decreased in rats with 
untreated DKA and that cerebral blood flow was directly tied to pCO2 (50). DKA 
commonly results in dehydration which could lead to, in combination with a low pCO2, 
increased vasoconstriction and consequently cerebral ischemia, hypoxia and increased 
capillary permeability (24, 51, 52). Increased capillary permeability would result in 
increased fluid flux across the BBB into the brain resulting in cerebral edema.  
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Several studies have attributed DKA-CE occurrence to rapid osmolar changes 
resulting from intravenous infusion during treatment (53-55). In a hyperosmolar 
environment, such as that commonly seen in hyperglycemia, cells in the brain generate 
intracellular osmoles in order to maintain their volume and osmolarity. Hyperglycemic 
rabbits showed an intracellular increase in various ionic solutes, sorbitol, lactate, urea, 
amino acids (56) and other idiogenic osmoles since identified as taurine and myoinositol 
(57-59). These changes were accompanied by equalization of brain and cerebrospinal 
fluid osmolality. When the hyperglycemia was corrected, the rabbits rapidly developed 
an osmotic gradient from brain to plasma, showed an increase in unidentified osmoles 
and other solutes in brain cells, an increased cerebral water content and most 
significantly, precipitation of cerebral edema (56). During treatment for DKA with fluids 
and insulin, plasma osmolarity decreases rapidly and if the intracellular osmoles do not 
dissipate accordingly, the result is that brain cells become relatively hyperosmolar to the 
serum, thus favouring inward fluid flux and consequentially, the formation of cytotoxic 
DKA-CE.  
Another proposed theory behind the pathophysiology of DKA-CE is the 
involvement of aquaporin channels, likely the result of fluid administration. Aquaporin 
channels are transmembrane channels whose function it is to transport water from 
extracellular to intracellular compartments. They are expressed in many epithelial and 
endothelial cells throughout the body as well as glial cells of the BBB. Aquaporins are 
highly expressed in the endfeet of astrocytes in contact with the abluminal surface of the 
cerebral endothelial cells (60). Aquaporin activity is pathologically associated with the 
formation of cerebral edema after injury in rats, both vasogenic and cytotoxic(61). They 
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have been shown to mediate cerebral edema in other pathological conditions such as 
traumatic brain injury and cerebral ischemia (61, 62). Acidotic conditions were shown to 
worsen cerebral edema in rats through the actions of aquaporin-1 (63).  
1.4 Blood-Brain Barrier 
The BBB is present in all mammals with a complex nervous system and plays a 
crucial role in keeping the brain isolated from peripheral circulation. The 
microvasculature in the brain provides a massive combined area for blood-brain gas, 
nutrient and waste exchange. A large functional surface area is critical due to the brain’s 
role as the most metabolically active organ in the body. With an average vessel diameter 
of < 8 µm, the microvessel functional area for blood-brain exchange in humans is 
approximately 100-200 cm
2
/g in brain tissue, or approximately 12-18 m
2
 total in an 
average adult (64). The BBB does not protect the areas of the brain involved in 
autonomic nervous control and endocrine function; it is present in every region of the 
brain except the circumventricular areas (65). 
The BBB is not a single protective brain partition as its name might imply, rather 
it refers to protective and exclusive characteristics that is inherent to brain vasculature 
itself, specifically the microvasculature. The BBB is composed of multiple cell types 
such as endothelial cells, astroglia and pericytes (66). The spatial arrangement of the 
BBB is very distinct. The luminal side of the barrier is composed of the cerebrovascular 
endothelial cells (CVEC) which form the vessel wall (Figure 1-1). The CVEC are 
arranged continuously, associating tightly together to form the tubular structure of the 
vessel. On the abluminal side of the vessel, underlying the CVEC is basal lamina which 
sheaths the capillary. Discontinuously associated with this surface are pericytes and 
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perivascular macrophages (45, 66). Further into the parenchyma are astrocytes, which 
project long endfeet onto the abluminal surface of the CVEC, and microglia (Figure 1-1). 
Astrocytes are the most abundant cell type interacting with CVEC and covers a majority 
of the microvascular abluminal surface (67). In terms of function, the term BBB refers to 
the actions and effects of the CVEC and to a lesser extent, pericytes and astrocytes (45, 
66). 
The main function of the blood-brain barrier is twofold. The first is to protect the 
brain and sensitive neural tissue from neurotoxic compounds, soluble factors, 
microorganisms, proteins and other cells that might be present in peripheral circulation. 
The second is to maintain homeostatic conditions in the neuronal extracellular 
environment by regulating the passage of blood-borne compounds into the brain 
parenchyma. In order to fulfill these roles, the BBB must be selectively permeable; it 
needs to be able to restrict entry of blood-borne macromolecular compounds with 
extreme prejudice, but at the same time, allow essential nutrients and compounds that the 
brain needs to function to access the brain parenchyma. The BBB accomplishes this 
through physical barriers and expression of selective transporters (64). Transporters 
specific for many important substances have been identified in the BBB, including ones 
specific for glucose compounds, amino acids, cholines, purines and monocarboxylic 
acids (68). The BBB functions to isolate cerebral circulation from peripheral circulation 
under physiological conditions. There are many macromolecules present in peripheral 
circulation that would be harmful to the brain. Proteins and factors such as albumin, 
prothrombin and plasminogen, if allowed to access the brain, are potent signalling 
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activators and can stimulate unwanted cell processes, resulting in damage and cell death 
(69-71).  
The BBB must also exclude peripheral neurotransmitters from the brain. Since both 
the central and peripheral nervous signalling uses the same neurotransmitters, it is 
imperative that the two systems remain independent of each other. Likewise, this also 
prevents excitotoxicity due to peripheral neurotransmitter imbalances spreading to the 
brain and disrupting signalling (72). The BBB also excludes immune cells from the 
cerebral environment. Activated immune cell infiltration into the brain can damage 
delicate neural tissue by releasing destructive factors and enzymes and turning on 
unwanted signalling pathways. As such, under normal physiological conditions, the brain 
is normally excluded from peripheral immune surveillance (72).  
Another function of the BBB is ion regulation. The BBB possesses a multitude of 
ion channels and transporters that preserve the ionic composition of the brain and keeps 
the extracellular space optimal for neuronal signalling. It is essential to keep the brain 
ionic content separate from peripheral ionic concentrations. For example, K
+
, an 
important ion in nervous signalling is held at ~2.5 mM in the brain, in spite of ionic 
fluctuations occurring in the periphery (64).  
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FIGURE 1-1. Schematic Diagram of the Blood-Brain 
Barrier. The BBB is found at the level of cerebral microvessels. 
Composing the wall of the vessel itself are continuous CVEC, 
tightly sealed against each other. Pericytes are located 
discontinuously on the abluminal side of the endothelial cells 
within the endothelial basal lamina. Perivascular macrophages also 
share this location. Extending cellular processes to make contact 
with the vessel from the neuropil are astrocytes. TJs and AJs 
function to seal the gaps between the adjacent endothelial cells. 
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1.5 Cerebrovascular Endothelial Cells 
The component of the BBB that is most responsible for its exclusionary properties 
are the CVEC. CVEC differ from endothelial cells elsewhere in the body by their relative 
lack of fenestrae. Fenestrae are pores that go through endothelial cells which allow for 
rapid exchange of material between blood vessels and the extracellular space without the 
use of transporters or channels and so in CVEC, this lack of fenestrae act to greatly 
reduce paracellular movement of substances, lending to the BBB’s permeability 
characteristics (45, 66). 
 CVEC possess tight junctions (TJ) which are complexes of transmembrane 
proteins whose primary purpose is to hold adjacent endothelial cells together and 
accordingly, they span the intercellular gap between adjacent endothelial cells. The TJs 
are also heavily involved in signal transduction in the cells. TJs are composed of a chain 
of many, almost continuous, but discrete points of intercellular contact, which are 
mediated by protein complexes. These are arranged in a belt-like formation around the 
apical end of the cell (45, 73). These points of tight contact between adjacent cells 
essentially occlude the paracellular passage. TJs act to increase electrical resistance 
across the endothelial layer as well as hindering paracellular transport of soluble 
compounds (45). TJs lend the BBB the functional properties of a single continuous cell 
membrane (64). This belt imparts polarity upon the cell by physically partitioning the 
apical and basal ends, allowing directional transport via asymmetrical expression of 
transporter proteins. TJs in the brain differ from those elsewhere in the body by being far 
tighter and more complex (64). 
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Tight junctions are composed of high levels of intercellular spanning 
transmembrane proteins, occludin and the claudins and the intracellular component, 
zonula occludens proteins (ZO) (Figure 1-2) (64). Occludin expression is higher in BBB 
TJs than in any other peripheral TJ, indicating a central role in the BBB (74). Of the over 
20 isoforms of claudin, only claudin-1 and -5 have been shown to be a component of 
BBB TJs (65). Both occludin and claudins are directly associated with the cytoplasmic 
scaffolding and signalling proteins ZO-1, -2, -3 and cingulin (64, 75). The TJ-ZO 
complex is also connected to the actin cytoskeleton. Many studies have associated 
disruption of occludin, claudin and ZO-1 with impaired BBB function (76-78). The final 
proteins involved in the TJs are junctional adhesion molecules (JAM). JAMs engage in 
heterogeneous and homogenous binding across the intercellular gap. Only JAM-A and -C 
are involved in the BBB TJs (79). Accordingly, the JAM family decreases BBB 
permeability and has been associated with an increased transendothelial electric 
resistance, inhibition of leukocyte extravasation and occludin localization (80).  
Another important feature of the CVEC in the BBB is the presence of adherens 
junctions (AJ). AJs are composed of transmembrane proteins called cadherins, anchored 
to the actin cytoskeleton in the cytosol via the catenins (α, β and γ) (Figure 1-2). In the 
intercellular space, vascular endothelial (VE)-cadherins homogenously bind to their 
adjacent cell counterpart, anchoring the 2 adjacent cells together (81). AJs play a role in 
cell-cell adhesion, signalling and transcriptional regulation (82). Perturbances to AJs have 
been shown to facilitate disruption of the endothelium (83, 84).  
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FIGURE 1-2. Schematic Diagram of the CVEC Junctional 
Complexes. Tight junctions are composed of three main proteins: 
occludin, claudin and junctional adhesion molecules (JAM). Intracellularly, 
these proteins are connected to the cytoskeleton by ZO-1. The junctional 
complex also consists of adherens junctions, which are composed of VE-
cadherin, α-catenin and β-catenin. Together, they are responsible for 
physically sealing adjacent endothelial cells together in order to prevent 
paracellular movement of luminal solutes as well as playing a role in signal 
transduction. (1)  
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1.6 Matrix Metalloproteinases 
Matrix metalloproteinases are a family of more than 20 zinc
2+
 dependent 
endopeptidases, found both secreted into the extracellular environment and membrane 
bound. In humans, there are 23, a number which includes the collagenases (MMP-1, -8, -
13, -18), the stromelysins (MMP-3, -10, -11), the matrilysins (MMP-7, -26) and the 
gelatinases (MMP-2, -9), as well as the membrane-type MMPs anchored to the cell 
surface by a C-terminal transmembrane domain (MMP-14 [MT1-MMP], -15 [MT2-
MMP], -16 [MT3-MMP] and -24 [MT5-MMP]) or a glycophosphatidylinositol (GPI) 
anchor (MMP-17 [MT4-MMP] and -25 [MT6-MMP]) (85-87).  
All MMPs are synthesized as preproenzymes with an endoplasmic reticulum-
targeting signal peptide and secreted as inactive zymogens or active enzymes (88). In 
terms of primary structure, MMPs are composed of several domain motifs, depending on 
the specific MMP. The catalytic domain is approximately 170 amino acids long and 
contains a zinc-binding motif inside the catalytic cleft (Figure 1-3). The zinc ion binds to 
a water molecule and is activated by a glutamate residue also located in the catalytic 
domain, in order to hydrolyze the target peptide bond (89). The propeptide domain, 
approximately 80 amino acids, is located at the N-terminus and is conserved among the 
MMP family (Figure 1-3). It contains a cysteine residue, also known as the cysteine 
switch that is able to bind to the catalytic site in order to suppress the proteolytic activity 
of the site in the propeptide. Some MMPs have a furin cleavage site between the pro-
domain and the catalytic domain. These enzymes are secreted in their active forms (90). 
Thus, the propeptide domain’s function is to maintain the inactivity of the MMP’s 
catalytic domain. Most MMPs contain a C-terminal hemopexin-like domain as well 
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(Figure 1-3), which functions mainly as a recognition site for specific substrates, though 
most MMPs retain their proteolytic activity without it (91). The hemopexin domain is 
however, absolutely necessary for the degradation of triple helical collagen (92). 
Similarly, the gelatinases have a series of three fibronectin type II inserts in the catalytic 
domain which function to recruit and bind gelatin (93). The hemopexin domain in some 
MMPs is also involved in mediating activation via other MMPs (94).  
Since the MMPs possess extremely potent proteolytic activity, their activity and 
expression is regulated at many levels. A large portion of MMP regulation takes place at 
the transcriptional level. MMP transcription is under the control of a number of factors 
such as activating protein (AP)-1, E26 transformation-specific translocation variant 
(ETV)-4, nuclear factor (NF)-κB (95) and hypoxia-inducible factor (HIF)-1α (96). A 
feature common to most MMPs is that they are inducible. MMP gene expression can be 
enhanced or suppressed by many factors. Examples of inducers of MMP gene expression 
are cytokines, growth factors, phorbol esters, actin disrupters, physical stress and 
oxidative stress (94, 97). Factors such as interleukins, interferons, epidermal growth 
factor (EGF) and basic fibroblast growth factor (bFGF) can all increase expression of 
MMPs through activation of the AP-1 or the ETV-4 elements (95). MMP gene expression 
can also be downregulated by transforming growth factor (TGF)-β, retinoic acids and 
glucocorticoids (94).  
Once secreted, MMPs are activated via cleavage of the propeptide domain, 
removing the inhibiting cysteine residue from the catalytic cleft (Figure 1-4) (94). This 
cleavage can be mediated enzymatically by other MMPs or proteases such as plasmin 
(98). Activation can also be mediated non-enzymatically, which involves disruption of 
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the inhibitory interaction between the Zn
2+
 residue and the cysteine residue. Thus, MMPs 
may be activated by S-nitrosylation or oxidation without cleavage of the propeptide 
domain (99, 100). Reactive oxygen species, mercurial compounds and denaturants may 
also nonenzymatically activate MMPs (101, 102). Nevertheless, in vivo, a majority of 
proMMP activation is mediated by tissue or plasma proteases. Numerous studies have 
suggested that the urokinase plasminogen activator (uPA)/plasmin system is a critical 
physiological activator of proMMPs, including proMMP-2, -3, -9, -12 and -13 (103-105).  
Catalytic MMP activation can also be mediated by other MMPs. For example, 
MT1-MMP, MT2-MMP and MT5-MMP have been shown to activate proMMP-2 (106-
108). As well, MMP-2, MMP-3 and MMP-13 are able to cleave and activate proMMP-9 
(109-111). ProMMP-2 can be activated by MT1-MMP, but this activation is tightly 
regulated by the complexing of tissue inhibitor of metalloproteinase (TIMP)-2 and MMP-
2 in cells (112). It is thought that the TIMP-2 subunit is required for the localization of 
the whole complex and thus, MMP-2 localization to the cell membrane where it can then 
be proteolytically activated by MT1-MMP (113). Thus, MMPs play a significant role in 
the modulation of each other and allow for even tighter regulation of activity. 
Once they are activated however, the proteolytic activity of MMPs is modulated 
either by nonspecific protease inhibitors, α2-macroglobulin or by a family of endogenous 
regulators called tissue inhibitor of metalloproteinases. There are 4 known members of 
the TIMP family: TIMP-1, -2, -3 and -4, ranging from 21-30 kDa in size. TIMPs 
noncovalently bind to and inhibit MMPs in a 1:1 stoichiometric ratio (114). The 
mechanism by which TIMPs inhibit the catalytic activity of MMPs is not well known. 
Studies have reported on the interaction between TIMP-1 and MMP-3: TIMP-1 possesses 
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a cysteine residue that is capable of chelating the catalytic Zn
2+
, thus disrupting its ability 
to carry out hydrolytic attack on other species. Additionally, TIMP-1 possibly obstructs 
any potential substrate binding in MMP-3 (115).  
The TIMPs do not show strong specificity for any particular MMPs; each TIMP 
can inhibit every MMP physiologically (116). However, differences between the TIMPs 
do exist. TIMP-1 and TIMP-2 have been observed to exhibit a preference for MMP-9 and 
MMP-2 respectively (117). TIMP-1 shows a lower affinity for the membrane-type MMPs 
(118). Additionally, TIMP-2 and TIMP-3 show a lower affinity for MMP-3 and MMP-7 
than TIMP-1 (119). TIMP-3 displays a wider range of MMP inhibition than the other 
TIMPs. The expression of TIMP-1 and TIMP-3 are thought to be highly inducible, 
whereas TIMP-2 expression is mostly constitutive (120).  
The major targets of the MMPs are the proteins that compose the extracellular 
matrix and basal lamina such as fibronectin, gelatin, collagen and proteoglycans; indeed, 
virtually all protein components of the extracellular matrix (ECM) can be degraded by 
the MMPs (88). They serve to modulate tissue architecture through turnover of the ECM 
and intercellular junctions. 
MMPs not only serve to degrade the ECM but also play a role in the generation of 
substrate cleavage fragments that have a biological function, and modify, activate or 
deactivate signaling molecules during inflammation (121). MMP-1, -3 and -9 have shown 
the most potential to regulate chemokine signaling (122). CXCL-8, a major inflammatory 
chemokine has been shown to be potentiated via MMP-8 and-9 processing (123, 124). 
Another well-known example is the effect of MMP-7 on the generation on CXCL-1 
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gradient. MMP-7 is able to release the chemokine into the ECM thereby generating a 
gradient to facilitate PMN infiltration. MMPs have also been shown to possess certain 
anti-inflammatory actions. For example, the cytokines CXCL-8 and CXCL-1 have been 
shown to be degraded and inactivated by MMP-9. Many MMPs can inactivate CXCL-12 
as well (125). Furthermore, in addition to inactivating pro-inflammatory cytokines, 
MMPs can also further process them into potent antagonists (126). Examples of this are 
the processing of CX3CL-1 and MCP-2 by MMP-2,  and MCP-1 by MMP-8 (127).  
Thus, MMPs represent a bidirectional level of regulation of inflammatory signals. 
Despite their important physiological roles, MMPs, through their ability to promote 
ECM breakdown and remodeling, have also been implicated in numerous pathologies. 
MMPs are also known to be an important contributor to pathological processes like 
arthritis, cancer and cardiovascular diseases (128-130). In particular, the gelatinases, 
MMP-2 and -9, have been shown to play a critical role in processes such as tumour 
invasion, angiogenesis and neovascularisation.  
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FIGURE 1-3. Schematic Diagram of the Common Different 
Functional Domains of the MMP Family. 
S, signal peptide; Pro, propeptide domain; Cat, Catalytic domain; Zn, Zinc 
residue; Fn, Fibronectin domain; Hpx, Hemopexin domain; I, Type I 
transmembrane domain; Cp, Cytoplasmic region; G, GPI anchor; ■, Furin 
cleavage site; V, Vitronectin insert. 
Classically, MMPs are composed of 3 main regions, the propeptide domain 
which inactivates the enzyme, the catalytic domain which facilitates target 
cleavage and the hemopexin/vitronectin domain which facilitates substrate 
recognition. Other domains include the signal peptide which locates the 
preproenzyme to the endoplasmic reticulum, Type 1 transmembrane domain 
and GPI anchor which serve to attach MT-MMPs and the furin cleavage site 
which facilitates activation via furin. (2) 
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FIGURE 1-4. Schematic Diagram of the Classic Activation of 
MMPs. The catalytic activity of the proenzyme is inhibited by the presence 
of propeptide domain which binds to and obstructs the catalytic cleft. 
Cleavage of the propeptide domain results in dissociation of the inhibitory 
complex and allows the MMP catalytic cleft to access and digest substrate.  
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1.7 Polymorphonuclear Neutrophils  
Polymorphonuclear neutrophils are the most abundant subtype of granulocyte 
white blood cell present in mammalian circulation. They are a key component of the 
innate immune system whose main role is to defend the body against microbes and 
pathogens during inflammation and are considered the “first line of defense”. PMN are 
constantly circulating throughout the body, moving through vessels in a nonadherent state 
and constantly probing the vascular wall. However, during inflammation, they transition 
into an adherent state. The endothelial cells of the vascular wall, upon inflammation, 
become activated and express many different membrane proteins such as E- and P-
selectin as well as ICAMs (131). The PMN themselves constitutively express L-selectin 
and P-selectin glycoprotein ligand (PSGL)-1 which can bind to all 3 types of selectin 
(132-134). Coupled with vessel dilation due to inflammation and flow stress, PMN are 
allowed to contact the vessel wall (135). Following inflammatory cytokine-mediated 
activation of endothelial cells, both expression of E-selectin and ICAM-1 are 
upregulated. L-selectin and PSGL-1, expressed on PMN, physically interact with E- and 
P-selectin, expressed by the endothelial cell, transiently recruiting the PMN to the 
endothelium. The PMN then “rolls” along the endothelium, jumping from selectin 
molecule to selectin molecule. Exposure to chemokines quickly triggers PMN to become 
more firmly adherent to the endothelium, a state change mediated by leukocyte integrins, 
leukocyte-function-associated antigen (LFA) and macrophage-associated protein (MAC)-
1 on the PMN interacting with ICAM-1 on the endothelial cell (134). The presence of 
chemokines during inflammation serves to activate integrins, thus increasing their 
binding strength immensely. At this stage, the rate at which PMN roll across the 
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endothelium is greatly diminished. Binding of leukocyte integrins to endothelial 
immunoglobulin (IgG)-superfamily molecules mediates leukocyte arrest (134, 136). Once 
its rolling has been arrested and the PMN firmly adheres to the endothelium, it is able to 
respond to inflammatory chemoattractants and undergoes chemotaxis. The PMN can then 
transmigrate through the endothelial layer into inflamed tissue, a process actively 
facilitated by endothelial platelet-endothelial cell adhesion molecule (PECAM)-1 and 
JAMs (Figure 1-5). 
PMN are able to coordinate the body’s immune system response as they can 
generate chemotactic signalling molecules, TNF and other cytokines such as IL-1β, 
monocyte chemoattractant protein (MCP) -1 and CXCL-1 to activate and direct immune 
cells (3, 137, 138). They can even direct macrophage differentiation into either a pro- or 
anti-inflammatory phenotype (138).  
PMN, however, are more recognized for their direct antimicrobial action. The 
cadre of microbicidal processes that PMN possess include their phagocytic function, their 
ability to release granules filled with proteolytic enzymes and their ability to produce 
reactive oxygen species (139, 140). The hallmark of all granulocytes and indeed, PMN, 
are the granules which form intracellularly during differentiation in the bone marrow 
(141). These granules can be divided into 3 main categories based on the proteins 
contained within them: primary/azurophilic granules, secondary/specific granules and 
tertiary/gelatinase granules. Azurophilic granules primarily contain myeloperoxidase 
(MPO) which facilitates peroxidation of cell membranes, 3 serine proteases, PMN 
elastase (HLE), proteinase-3 (PR-3) and cathepsin G (CTSG) as well as defensins and 
lysozyme. Specific granules contain lactoferrin, an enzyme that sequesters away iron and 
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copper, MMP-8 and lysozyme. Tertiary granules contain MMP-9 and MMP-25 (139). 
PMN also possess secretory vesicles which contain plasma proteins, complement 
receptor and Fc receptors (142). The type of granule produced coincides with the 
differentiation stage of the PMN such that azurophilic granules are indicative of relatively 
young PMN while gelatinase granules are that of mature PMN (143). These granules are 
released in a process called degranulation which occurs upon activation, during and after 
the transmigration of PMN through the endothelial layer into tissue. Different granules 
are released at different times during PMN extravasation. Secretory vesicles are 
exocytosed upon contact with the endothelium and so act to facilitate a further immune 
response (139, 144). In general, the order of granule subtype released depends upon the 
ease of mobility. Secretory vesicles are most easily mobilized and are therefore, released 
first, onto the PMN membrane within the bloodstream and at the endothelial surface. 
Tertiary granules are the second easiest mobilized granule and are released as PMN are 
moving through the endothelial layer whereas primary and secondary granules are the 
most difficult to mobilize and are thus, released directly at the site of inflammation (3). 
The release of these highly destructive enzymes is crucial for antimicrobial activity. 
However, unwanted or improper release due to severe inflammation can cause serious 
damage to tissue. Pathologically, PMN play a deleterious role in inflammatory conditions 
such as ischemia-reperfusion injury and sepsis (145-147). 
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FIGURE 1-5. Diagram of PMN Activation and Recruitment to the 
Vascular Endothelium. During inflammation, endothelial cells express P- 
and E-selectin on the cell surface. These proteins interact with ligands on the 
PMN resulting in margination and rolling of PMN on the endothelial surface. 
Adhesion molecules of IgG-superfamily (e.g., ICAM-1) expressed on vascular 
endothelium interact with PMN adhesion molecules (e.g., integrins) resulting 
in PMN capture and firm adhesion. Subsequently, PMN migrate across the 
endothelial barrier (a process mediated by PECAM-1 and JAMs) in response 
to chemotactic stimulus. Once inside the infected/inflamed tissue, PMN 
release their vesicles and microbicidal enzymes in a process called 
degranulation. (3) 
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1.8 PMN Serine Proteases 
The PMN serine proteases (NSP), as previously mentioned, include HLE, PR-3 
and CTSG. The major sources of these serine proteases are PMN, but also include 
monocytes (148, 149) and other granulocytes such as eosinophils (150). Similar to 
MMPs, NSPs are expressed as proenzymes (151-153) and require processing into active 
forms. However, unlike MMPs which are secreted as proenzymes, NSPs are generally 
processed into their active form prior to packaging into their respective granules and are 
therefore, active upon release (154).  
These homologous proteases depend upon a catalytic triad formed from aspartate, 
histidine and serine (154). As its name implies, serine proteases contain a catalytic serine 
residue. The catalytic unit utilizes the hydroxyl group on the residue and free H2O to 
hydrolyze the target peptide bond (155). They are all neutral proteases with their optimal 
pH range being around 7.5-8.5 (154, 156).  
Physiologically, they are irreversibly inhibited by the endogenous protease 
inhibitor family, the serpins, such as α1-proteinase inhibitor and α1-antichymotrypsin, or 
to a lesser extent, α2-macroglobulin (154). Interestingly, α1-proteinase inhibitor displays 
specificity for HLE but nevertheless, inhibits all serine proteases (157). A conserved loop 
domain on α1-proteinase inhibitor and other serpins, binds to the protease catalytic site. 
When the loop is cleaved, the inhibitor undergoes a rapid conformational change, 
trapping the NSP and the inhibitor in an inactive state (158). These inhibitors are 
extremely prominent in plasma, in far excess of circulating NSPs (157). However, it is 
thought that during inflammation, the release of these proteases is significant enough to 
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overwhelm the local inhibitory capacity and exert its actions for a brief period of time 
(159, 160).  
Intracellularly, NSPs are stored in phagolysosomes and act to digest phagocytised 
pathogens. They are, however, more recognized for their extracellular role in ECM 
destruction and peptide cleavage. NSPs are able to cleave a variety of ECM components 
including elastin, fibronectin, laminin, collagens and proteoglycans (161-163). They are 
also able to cleave a wide range of plasma proteins such as complement and factor VII 
(164, 165). Due to their extremely broad range of overlapping substrates, it is believed 
that they are non-specific proteases.  
NSPs also play a role in innate immunity (166) and regulation of the 
inflammatory response (167). NSPs have been shown to augment the inflammatory 
cytokine response. HLE can induce release of CXCL-8 (168-171), IL-33 and GM-CSF 
(170). PR-3 has been shown to be able to induce the release of CXCL-8 (171), active IL-
18 which can promote PMN activation (172, 173), TNF converting enzyme and IL-1β 
converting enzyme (174). The NSPs can not only induce cytokine release from other cells 
but are also able to modify the biological function of cytokines. For example, both TNF-α 
and IL-6 are cleaved and inactivated by all three of the NSPs (175, 176). PR-3 was also 
shown to be able to generate more active forms of CXCL-8 whereas HLE was shown to 
inactivate it (177, 178). HLE has also been shown to cleave IL-2, a potent T-cell 
activator, into inhibitory fragments (179). NSPs may also function to facilitate PMN 
transmigration through the endothelium. NSPs could, potentially, be used to degrade 
various proteins of the ECM and impeding intercellular junctions (180-182). Interestingly 
though, it has been shown in some studies that inhibition of the various NSPs does not 
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inhibit neutrophil migration (183), indicating an incomplete understanding of the 
mechanism by which PMN penetrate the endothelium.  
Pathologic regulation of NSPs has been observed in many diseases such as 
ischemia-reperfusion injury, arthritis and emphysema. As powerful proteases, much of 
the focus has been on their proteolytic activity. NSPs have been shown to contribute to 
lung injury due to its ability to degrade both endothelial VE-cadherin, thereby promoting 
microvascular permeability and E-cadherin which contributes to alveolar flooding (184). 
HLE has been shown to be associated with fatal sepsis (147) and is thought to function by 
disrupting endothelial integrity. This junctional disruption could be mediated by NSPs 
(182, 185). 
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1.9 Rationale 
Pediatric DKA has been linked to numerous intracranial cerebrovascular 
pathologies such as vasogenic edema and hemorrhagic stroke (19, 186-189). Although 
the exact mechanisms of these crises are not known, a common element to all 
cerebrovascular complications is endothelial dysfunction. A prominent theory is that 
DKA results in the breakdown or destabilization of the brain endothelium, increasing 
endothelial permeability and allowing solutes and water to cross into the extracellular 
space. BBB disruption was observed in conjunction with DKA in examination of brain 
tissue from 2 deceased human patients. In the same study, DKA was associated with 
decreased expression of numerous tight junction proteins such as occludin, claudin-5, 
ZO-1 and JAM-A in all areas of the brain, indicating a dysfunction in the formation or 
composition of the TJs at the BBB (190). Functionally, increased albumin leakage into 
the brain from peripheral circulation was also observed in the study, providing direct 
evidence of compromised BBB function. 
Pathological MMP activity is widely implicated in BBB disruption (98, 191-193). 
Increased MMP expression and activity have been seen in severe sepsis, traumatic brain 
injury, cerebral ischemia, bacterial meningitis, stroke and migraine and have been linked 
to increased permeabilization of the BBB (96, 192, 194-199). MMPs can contribute to the 
disruption of the BBB by directly degrading TJs between the CVEC, leading to increased 
water and solute movement across the BBB (200). Increased MMP-2 and -9 activity and 
expression was associated with degradation of claudin-5 and occludin in cerebral vessels 
following ischemic reperfusion injury in rats, indicating decomposition of the TJs (201).  
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MMPs can also contribute to BBB or any endothelial disruption by releasing 
permeability-inducing factors that are normally sequestered away in the ECM such as 
vascular endothelial growth factor (VEGF), thus facilitating an increase in biological 
activity (202, 203). It has also been demonstrated that MMPs are able to proteolytically 
activate latent factors such as TGF-β (204), which has been shown to significantly 
increase endothelial permeability (205).  
MMPs are known to play a role in cytokine processing and generation of 
biologically active fragments (127). Processing of the cytokines, CXCL-8, CXCL-5 and 
CXCL-6 by both MMP-8 and -9 has been shown to potentiate their chemotactic effects 
and biological function (206). MMP-mediated cytokine processing acts to facilitate 
leukocyte activation and migration, thus facilitating endothelial disruption indirectly 
(127).  
Previous work in our lab has shown that DKA is associated with a pro-adhesive 
phenotype of endothelial cells (41). DKA also results in increased circulating pro-
inflammatory cytokines such as CXCL-8, CXCL-1 and IFN-α2, which results in 
increased activation and adhesion of PMN (37). PMN possess granules full of destructive 
enzymes which are released upon activation. PMN-derived MMP-9 can facilitate the 
pathological breakdown of the BBB during ischemic-reperfusion injury (191). The PMN 
serine proteases, elastase and cathepsin G were shown to be able to induce a disruption of 
the BBB and increase vascular permeability in rats (207). Additionally, PMN elastase and 
PR-3 were shown to be able to induce apoptosis of endothelial cells (208, 209). Activated 
PMN and their associated proteases have been associated with widespread endothelial 
damage (207, 210, 211). MPO generates extremely powerful oxidizing species such as 
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hypochlorous acid from H2O2 and has been shown to severely disrupt BBB function in 
vitro and in vivo (212). It also plays a role in generation of endothelial intracellular 
oxidative species and drives apoptosis in some cell types (213, 214).  
Similar to the MMPs, the PMN protease are known to play a role in the processing 
of cytokines, rendering them either active or inactive. For example, elastase and PR-3 are 
known to be able to cleave immunoglobulin, IL-2 receptor (215), TNF-α (175) and TNF-
α converting enzyme (174). All 3 serine protease also process CXCL-8 and CXCL-1 
(177). 
Previous experiments done in our lab have shown leukocyte adherence to the 
endothelium under DKA conditions indicating significant leukocyte involvement. We 
believe that the intracranial vascular complications often seen in DKA are the result of 
the destructive enzymes released by adherent leukocytes during the DKA inflammatory 
response. Therefore, is it believed that disturbance in the BBB and other endothelial 
barriers are exacerbated by the presence of DKA through perturbances in circulating 
leukocyte-derived MMPs as well as azurophilic enzymes. 
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1.10 Hypothesis 
I hypothesize that children with DKA will present with increased plasma 
leukocyte-derived proteases and enzymes compared to insulin-controlled T1DM. In 
addition, enzyme levels will correlate with DKA severity and result in brain 
microvascular junctional disruption.  
1.11 Objectives 
I. To examine plasma MMPs/TIMPs in pediatric DKA patients and to correlate 
these with DKA severity. 
II. To (1) examine the systemic PMN azurophilic enzyme profile of pediatric 
DKA patients and to correlate these with DKA severity and (2) to examine 
the potential for PMN azurophilic enzymes to disrupt brain microvascular 
intercellular junctions.   
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CHAPTER 2: DYNAMIC REGULATION OF PLASMA MATRIX 
METALLOPROTEINASES IN HUMAN DIABETIC KETOACIDOSIS 
  
  
A version of this chapter has been submitted for review. 
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2.1 Introduction 
Type 1 diabetes mellitus (T1DM) is a chronic affliction that occurs predominantly 
in children, and is expected to double over the next decade (1). The most frequent 
complication of T1DM is diabetic ketoacidosis (DKA), a state of insulin deficiency that 
leads to metabolic acidosis, hyperglycemia and ketonemia (2). DKA is associated with 
intracranial cerebrovascular-related complications such as stroke (3), hemorrhage (4) and 
vasogenic edema (5).  
DKA is associated with systemic inflammation (6-9). We recently reported that 
DKA elicits significant elevations in the chemokines CXCL-1 (GROα) and CXCL-8 (IL-
8), resulting in leukocyte adhesion to human-derived cerebral microvascular endothelium 
(10). Adhered leukocytes can release substances that mediate endothelial damage and 
vascular destabilization (i.e., matrix metalloproteinases [MMP]) (11).  
MMPs are a family of endogenous proteases that include collagenases (MMP-1,-
8,-13), stromelysins (MMP-3,-10,-11), matrilysins (MMP-7,-26), gelatinases (MMP-2,-9) 
and membrane-type MMPs (MMP-14, -15, -16, -17,-24, -25) (12). Leukocytes are a 
major source of circulating MMPs during inflammation (13). Alterations of MMPs and 
their endogenous tissue inhibitors (TIMPs) are observed in inflammation-related 
pathologies (14-16) and MMPs have potential to compromise cerebrovascular endothelial 
barrier function (17-19).  
We hypothesized that DKA is associated with elevated leukocyte-derived MMPs. 
Our aims, using blood from acute pediatric DKA patients, were (1) to measure plasma 
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levels of MMPs/TIMPs, (2) to correlate the MMP/TIMP levels with DKA severity, and 
(3) to determine if MMPs are leukocyte-derived.  
2.2 Methods 
This study was approved by the Health Sciences Research Ethics Board at 
Western University. Patients were recruited at our regional tertiary care centre; the 
Children’s Hospital, London Health Sciences Centre (London, ON). 
2.2.1 Human Subjects 
Consent was obtained from the legal guardians of all pediatric patients admitted 
with DKA, and both legal guardian consent and patient assent were obtained for T1DM 
insulin-controlled patients. Biochemical diagnostic criteria for DKA included 
hyperglycemia > 11 mmol/L, bicarbonate < 15mmol/L and ketonurea (20). DKA is 
classed according to severity of acidosis as mild DKA (venous pH < 7.3), moderate DKA 
(pH < 7.2) or severe DKA (pH < 7.1) (21, 22). The majority of DKA cases used in this 
study were severe. Clinic patients with insulin-controlled T1DM (HbA1c < 10% and no 
DKA for > 3 months) served as controls (CON). 
2.2.2 Blood Collection and Processing 
Blood for research purposes was obtained on hospital presentation at the time of 
clinically-indicated blood draws. Blood was drawn into citrate-containing tubes 
(Vacutainers
®
, BD Biosciences, Mississauga, ON) by certified nursing personnel, placed 
on ice, and immediately transferred to the Translational Research Centre facility for 
processing by standard operating procedures (www.translationalresearch.ca, London, 
ON) (23, 24). Briefly, blood was centrifuged at 1500 g for 15 min (4
o
C), and the upper 
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plasma layer collected into 250 µl aliquots. Next, the buffy coat was removed and also 
aliquoted. Both plasma and buffy coat aliquots were immediately frozen at −80 °C until 
usage. When needed for experiments, plasma was thawed and maintained briefly on ice. 
Freeze-thaw cycles were avoided. 
2.2.3 MMP/TIMP Antibody Microarray 
The plasma concentrations of MMP-1, MMP-3, MMP-8, MMP-10, MMP-13, 
TIMP-1, TIMP-2 and TIMP-4 were measured using a multiplex enzyme-linked 
immunosorbent assay (ELISA)-based array, the Quantibody® Human MMP array 
(RayBioTech, Inc.; Norcross, GA) which utilizes a biotin conjugated detection antibody 
and a streptavidin-labeled Cy3 equivalent dye that produces a fluorescent signal intensity 
proportional to concentration. Undiluted plasma was loaded into each well and assayed 
according to the manufacturer’s instructions. The completed arrays were then shipped 
back to the manufacturer for data extraction and analysis. 
2.2.4 MMP Gelatin Zymography 
MMP-2 and MMP-9 were assayed using gelatin zymography, as we reported 
previously (16). Plasma samples were diluted 1:1 in PBS. Protein in the diluted plasma 
samples was then quantified using the bicinchoninic acid assay (Thermo Fisher 
Scientific, Waltham, MA). Equal amounts of protein (75µg) were mixed with non-
reducing sample buffer and loaded in each well. Samples were run on a 10% sodium 
dodecyl sulphate polyacrylamide electrophoretic gel impregnated with 0.1% gelatin (m/v) 
under non-reducing conditions at 140V until the dye front left the gel. Enzymes were re-
natured in 50mL of 2.7% Triton X-100 (v/v) in distilled water with gentle shaking for 1 
hour at room temperature. After washing gels for 5 minutes in 50mL of distilled water on 
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a rotary mixer, the gels were developed in 50mL of developing buffer (50mM Tris-base 
pH 7.4, 200mM NaCl, 5mM CaCl2·2H2O) containing 1 cOmplete EDTA-free Protease 
Inhibitor Cocktail Tablet (Roche Applied Science, Indianapolis, IN) for 20 hours at 37°C 
(5% CO2). The gels were then stained with 0.5% Commassie Brilliant Blue R-250 
(Roche Diagnostics, Mississauga, ON) for 1 hour and then de-stained with a solution 
consisting of 30% MeOH (v/v) and 10% acetic acid (v/v) until bands of proteolysis were 
clear. Gels were scanned using a GS-690 densitometer (Bio-Rad Laboratories, Hercules, 
CA). Proteolytic bands were quantified as a ratio of the optical density of the 
experimental band to a known amount of human recombinant active MMP-2 standard 
(EMD Millipore, Etobicoke, ON) run on the same gel. Quantification of bands was 
performed using image quantification software (FroggaBio, Toronto, ON). Negative 
control zymograms were incubated in the presence of 20 mM ethylenediaminetetraacetic 
acid (Bioshop, Burlington, ON). 
Since the zymography technique measures protein as gelatinolytic activity as 
opposed to concentration, it was necessary to estimate the concentration of MMP-9 from 
proteolytic bands in a separate experiment. In order to quantify the MMP-9 present in a 
zymogram, identical volumes (1.0 µL) of three representative age- and sex-matched 
sample pairs were loaded and run on a zymogram as previously described. A dose-
response curve of a known amount of recombinant human active MMP-9 standard (EMD 
Millipore) was loaded and run on the same gel. The optical density of the proteolytic 
bands were measured as previously described and the standard dilutions were used to 
generate a standard curve to quantify the mass of MMP-9 present in a given proteolytic 
band. The plasma concentration (ng/mL) of MMP-9 in each experimental condition was 
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estimated by adjusting the average mass of MMP-9 in the zymogram for the volume of 
plasma initially loaded in the gel and the dilution factor. 
2.2.5 Quantitative Real-Time PCR 
Quantitative real-time polymerase chain reaction (qPCR) was used to quantify the 
expression of the genes found to be significantly altered in zymography and the ELISA 
array. RNA was isolated using TRIzol® LS Reagent (Life Technologies, Grand Island, 
NY) from buffy coat extracted from CON and DKA patients then subjected to Turbo 
DNA-free (Life Technologies) digest according to the manufacturer's suggested protocol. 
The RNA integrity number (RIN) of the samples was assessed using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Mississauga, ON) at the London Regional Genomics 
Center, samples had an RIN > 6.7. 2µg of RNA from each sample was then reverse 
transcribed using iScript™ Advanced Reverse Transcriptase (Bio-Rad). TaqMan® Gene 
Expression Assays (Life Technologies) were used with the SensiFAST™ Probe No-ROX 
kit (Bioline, London, UK) for qPCR. The assay IDs were MMP-2 (Hs01548727_m1), 
MMP-8 (Hs01029058_m1), MMP-9 (Hs00957562_m1) and TIMP-4(Hs00162784_m1). 
Target genes were normalized to β-actin (Hs01060665_g1) and GAPDH 
(Hs02758991_G1). The reaction was carried out with CFX96 Real-Time PCR Detection 
System-IVD (Bio-Rad).The PCR protocol was as follows: 2 minute initial denaturation at 
95°C, 70 cycles of 10 second denaturation at 95°C, 30 second annealing and extension at 
60°C. 
2.2.6 Statistical Analysis 
All calculations were done using Graphpad Prism software. Data was assessed 
with the Mann-Whitney U test for nonparametric data with Bonferroni’s correction for 
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multiple comparisons when applicable. Correlation analysis utilized Spearman’s rank 
correlation coefficient. All data is presented as mean ± standard error (SEM). Statistical 
significance utilized a P value of < 0.05. 
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2.3 Results 
Study patients 
Plasma was obtained from T1DM patients either in an acute DKA or in an 
insulin-controlled state (CON). The two groups were age- and sex-matched (n=16/group; 
Table 2-1). Patients with DKA had significantly higher HbA1c values, compared to those 
with insulin-controlled T1DM (P<0.001), indicating elevated blood glucose over the 
previous three months. DKA patients all had elevated blood glucose (27.4±8.3 mmol/L) 
and moderate to severe metabolic acidosis (pH 7.00±0.03; PCO2 20.8±2.3 mmHg; HCO3
-
 
5.9±0.8 mmol/L; lactate 2.9±0.7 mmol/L).  
ELISA array measurements of plasma MMPs/TIMPs 
In order to generate an MMP/TIMP profile, the levels of MMP and TIMP species 
were measured in plasma from both DKA and CON groups. Out of all the plasma MMP 
and TIMP species measured on the array, only MMP-8 and TIMP-4 were found to be 
significantly increased in DKA (17.1-fold increase and 2.1-fold increase, respectively), as 
compared to CON (Table 2-1; P < 0.001; n=16 per group). These results demonstrate 
selective elevation of the collagenase MMP-8, and to a lesser extent, TIMP-4.  
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TABLE 2-1. Clinical Data and Plasma MMP/TIMP Levels in Type-1 Diabetes 
Patients.  
Either insulin-controlled (CON) or with acute diabetic ketoacidosis (DKA) (n= 16/group)  
 
 
  CON DKA P value 
Clinical Data    
   Mean age (years) 11.4 ± 1.0 11.7 ± 0.8 0.830 
   Male: Female 
ratio 
8:8 8:8 1.000 
   HbA1c 8.3 ± 0.3 11.7 ± 0.5 < 0.001 
MMP/TIMP 
Microarray 
   
   MMP-1 1.22 ± 0.72 2.24 ± 1.18 0.865 
   MMP-3 6.04 ± 1.34 9.45 ± 1.72 0.086 
   MMP-8
a
 39.96 ± 12.90 684.25 ± 307.59 < 0.001 
   MMP-10 0.28 ± 0.04 0.60 ± 0.16 0.181 
   MMP-13 0.03 ± 0.01 0.04 ± 0.02 0.201 
   TIMP-1 5.46 ± 1.75 10.70 ± 2.28 0.318 
   TIMP-2 4.42 ± 0.37 4.71 ± 0.47 0.925 
   TIMP-4 1.08 ± 0.12 2.26 ± 0.22 < 0.001 
a; Concentrations of MMP-8 are reported in pg/mL (mean ± SEM). All the rest 
are all reported in ng/mL (mean ± SEM). To control for repeated measures in 
MMP/TIMP analyses, a P value<0.005 was considered significant. Boldface 
indicates significant P value. 
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Gelatin zymography for MMP-2 and MMP-9 
To assess MMP-2 and MMP-9 levels in DKA, we assayed gelatinolytic activity of 
both CON and DKA plasma via zymography. A representative zymogram of 3 different 
CON/DKA sample pairs is shown in Figure 2-1A. MMP-9 was significantly increased 
1.7 fold in DKA plasma compared to CON plasma (Figure 2-1B; ~100 kDa MW; P < 
0.05). Conversely, MMP-2 was significantly decreased 2.8 fold in DKA plasma 
compared to CON plasma (Figure 2-1C; ~70 kDa MW; P < 0.001). In addition, DKA 
plasma had a faint ~135 kDa band on gelatin zymography that may reflect a well-
described complex of MMP-9 with neutrophil-gelatinase-associated lipocalin (25). 
Overall, these results suggest distinct opposing regulation of the MMP gelatinases by 
DKA in children, and a potential neutrophilic source of MMP-9.  
The plasma concentration of MMP-9 was estimated from zymography (data not 
shown) using 3 age-/sex-matched sample pairs (CON ~670 ng/mL vs. DKA ~1,509 
ng/mL). 
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FIGURE 2-1. Gelatin Zymography of DKA Plasma. Gelatin zymography was used 
to measure both MMP-2 and MMP-9. (A) A representative zymogram of 3 plasma 
DKA/CON experimental pairs. The right-most lane contains a molecular weight ladder. 
MMP-9 is represented at ~100 kDa, likely representing the latent form. MMP-2 is 
represented by the bands at ~70 kDa, also representing the latent form. (B) MMP-9 levels 
in DKA plasma were significantly increased relative to CON plasma. Results are 
presented as relative optical density. (C) MMP-2 levels in DKA plasma were 
significantly decreased from CON plasma. Results are presented as relative optical 
density. *P<0.05; ***P<0.001; n= 16/group. 
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MMP-8 and MMP-9 correlated with DKA severity  
In order to determine correlations between altered MMP/TIMP levels in DKA 
plasma and a clinically relevant parameter, correlation analysis was applied to data points 
graphed as MMP concentrations versus blood pH (acidotic blood pH reflects greater 
DKA severity). Both MMP-8 and MMP-9 were inversely correlated with blood pH 
(Figure 2-2A; rs= -0.71; P < 0.01 and Figure 2-2B, rs= -0.60, P < 0.05, respectively). In 
contrast, no correlations could be determined for either MMP-2 or TIMP-4 (rs= 0.26, P= 
0.34 and rs= 0.07, P= 0.80, data not graphically shown). These results suggest that MMP-
8 and MMP-9 plasma levels are correlated with DKA severity. 
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FIGURE 2-2. Plasma MMP Correlation with pH in DKA. MMPs correlate with 
DKA severity. (A) MMP-8 plasma concentrations were inversely correlated with blood 
pH in DKA patients. A best-fit line was added to aid in visual interpretation of the graphs 
(rs= -0.714, P= 0.0019, n= 16). (B) MMP-9 plasma concentrations were inversely 
correlated with blood pH in DKA patients. A best-fit line was added to aid in visual 
interpretation of the graphs (rs= -0.6024, P= 0.0135; n= 16). 
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Leukocyte mRNA expression of MMPs and TIMPs 
To determine whether the observed changes in MMP-2, MMP-8, MMP-9 and 
TIMP-4 were leukocyte derived, we assayed the respective gene mRNA levels with 
qPCR. MMP-8, MMP-9 and TIMP-4 gene expression was significantly increased in 
leukocytes from DKA patients, as compared to CON patients (Figure 2-3; 45.0, 6.3 and 
31.8 fold-change respectively; P < 0.0025). In contrast, MMP-2 showed no significant 
changes. These results suggest that elevated plasma MMP-8, MMP-9 and TIMP-4 are, at 
least in part, leukocyte derived. 
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FIGURE 2-3. Leukocyte MMP Gene Expression in DKA. Elevated MMPs/TIMP-4 
in DKA plasma are leukocyte-derived. Gene expression of MMP-8, MMP-9 and TIMP-4 
were significantly elevated in DKA, as compared to CON patients. Target gene 
expression is normalized to β-actin and GAPDH and presented as fold-change from 
CON. N.S.: not significant; **P < 0.005 (controlled for repeated measures); n= 5/group 
for MMP-2, n= 7/group for all other genes. Mean CT values for CON and DKA samples 
were MMP-2 (37.73; 37.35), MMP-8 (29.91; 35.09), MMP-9(25.83; 28.11), TIMP-4 
(39.40; 43.08), respectively.  
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2.4 Discussion 
In this study, we report that DKA induced a markedly altered plasma MMP/TIMP 
profile in acute pediatric DKA patients, and that both MMP-8 and MMP-9 concentrations 
correlated with DKA severity. DKA-induced MMPs were, at least in part, leukocyte 
derived. MMP-8 and MMP-9, at concentrations similar to those measured in DKA 
plasma, have been reported to disrupt brain endothelial cell tight junctions. To our 
knowledge, this study is the first to employ human DKA tissues in relation to 
pathological changes in systemic proteases.  
Our current data, taken together with our previously reported results (10), show 
that DKA is an inflammatory state associated with highly elevated levels of systemic 
cytokines (IL-6 and IFN-α2), chemokines (CXCL-1 and CXCL-8) and MMPs (i.e., 
MMP-8 and MMP-9). MMPs have diverse actions that that may involve exacerbation of 
existing inflammatory cascades (26), as well as direct actions on the microvasculature 
(27). This latter action of MMPs is particularly intriguing given that DKA induced 
leukocyte adherence to the brain microvasculature (10) and that the DKA-induced MMPs 
appear to be leukocyte-derived. 
MMP-8 was significantly elevated in DKA plasma and plasma MMP-8 
concentrations correlated with DKA severity. MMP-8 mRNA was elevated in leukocytes 
from DKA patients, a finding that is consistent with the almost exclusive production of 
MMP-8 by neutrophils (28, 29). The primary substrates for MMP-8 are the fibrillary 
collagens, I, II, III, as well as other extracellular matrix components (13). Vascular 
leukocyte trafficking and blood brain barrier disruption are mediated by MMP-8, and 
may involve cleavage of the endothelial cell tight junction proteins (30, 31). Our results 
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raise the possibility that the DKA-induced elevations in MMP-8 may contribute to 
cerebrovascular endothelial perturbations. 
MMP-9 was significantly increased in DKA plasma and plasma MMP-9 activity 
on zymogram correlated with DKA severity. The 100 kDa MMP-9 band suggests that the 
plasma MMP-9 is primarily a latent form (32, 33), but it is available for immediate 
activation. Neutrophils are a likely source of MMP-9 in DKA plasma given that increased 
MMP-9 mRNA was found in our leukocyte preparation, that a ~135 kDa band was 
observed on zymography that likely reflects a well-described complex of MMP-9 with 
neutrophil-gelatinase-associated lipocalin (25), and that early rises in plasma MMP-9 
have been attributed to neutrophil degranulation of stored MMP-9 (34). Delayed sources 
of plasma MMP-9 may include de novo synthesis via monocytes, lymphocytes, dendritic 
cells and endothelial cells (35). CXCL-8, known to be elevated in DKA, stimulates 
expression of MMP-9 (36, 37). MMP-9 can proteolytically degrade virtually all 
components of the extracellular matrix, and MMP-9 has the ability to disrupt components 
of junctional complexes in the brain microvasculature (27, 38). 
Our data suggests that plasma MMP-2 (~70 kDa) is decreased in DKA, possibly 
due to the hyperglycemic conditions that are characteristic of DKA (39). Decreased 
MMP-2 facilitates increased extracellular matrix deposition in vascular structures as a 
primary function of MMP-2 is extracellular matrix turnover (40). Indeed, decreased 
plasma levels of MMP-2 during DKA may contribute to chronic thickening of basal 
lamina and pathologic remodeling of the extracellular matrix over multiple DKA 
episodes.  
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Plasma TIMP-4 was also mildly elevated in DKA and was at least partially 
leukocyte-derived. Increases in TIMP-4 are likely due to increased monocytic expression. 
While TIMP-4 is considered a broad MMP inhibitor, it also displays some specificity 
against MMP-2 (41) and has the ability to prevent cell surface activation of MMP-2 (42). 
Depressed levels of MMP-2, in conjunction with elevated plasma TIMP-4, could 
facilitate extracellular matrix deposition. 
The actions of elevated plasma MMP-8 and MMP-9 in DKA are largely 
unknown. The main role attributed to MMPs during inflammation is its proteolytic ability 
on cellular junctions, however, MMPs are now known to play a role in cytokine 
processing and generation of biologically active or inactive fragments (26). Processing of 
the DKA-relevant chemokine CXCL-8 (10), by both MMP-8 and MMP-9, has been 
shown to potentiate its chemotactic effects and biological function (43), MMP-mediated 
cytokine processing acts to facilitate leukocyte migration, thus facilitating endothelial 
disruption indirectly (26). 
Higher concentrations of plasma MMP-8 and MMP-9 were associated with 
greater DKA severity (lower pH). Acidic pH directly stimulates the induction and release 
of cellular MMPs (44-47), and a lower pH is associated with markedly more MMP-8 and 
MMP-9 catalytic activity (44, 48-50). Thus, DKA patients, by virtue of their blood acidic 
pH, are particularly susceptible to the deleterious actions of MMP-8 and MMP-9. DKA 
correction with intravenous fluid and exogenous insulin administration normalizes the 
blood pH. While MMP-8 activity would decrease with increasing pH to normal values 
(48, 50), MMP-9 still maintains much of its catalytic activity (44, 49). In contrast, MMP-
67 
 
 
 
2 is noted to have decreased activity in acidic pH conditions (51), perhaps resulting in 
further reduced MMP-2 functional capacity.  
MMPs have been shown to increase permeability of human brain microvascular 
endothelium (i.e., vasogenic edema) (18, 19), likely by degrading tight junction proteins, 
including occludin, claudin-5 and ZO-1 (17). Active MMP-9 has been most thoroughly 
investigated, and exerts actions at concentrations (100-250 ng/ml) that are compatible 
with those measured for latent MMP-9 in DKA plasma (1,509 ng/ml) (17, 18). The 
sequential addition of MMPs (i.e., MMP-8) has been demonstrated to boost substrate 
degradation (52). 
Our study has several limitations worthy of discussion. First, our data showed a 
leukocyte origin of the MMP-8 and MMP-9, but we cannot rule out other cellular 
contributions (i.e., endothelial cells). Future studies should try to isolate leukocyte 
subtypes for analyses from fresh blood samples. Second, the measured concentrations of 
MMP-8 and MMP-9 might not represent the exact concentrations encountered at the 
brain endothelial cell layer. The MMP concentrations adjacent to leukocytes adhered to 
the brain microvascular endothelium are almost certainly higher, but we have no way of 
measuring concentrations in such localized domains.  
In summary, our data show for the first time that DKA is a disease state 
associated with dynamic regulation of plasma MMPs. In particular, leukocyte-derived 
MMPs (e.g., MMP-8 and MMP-9) correlated with disease severity and they have the 
potential to degrade key components of the cerebrovascular tight junctions, perhaps 
explaining the susceptibility of children with DKA to intracranial complications. Our 
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data, provide a plausible mechanism for DKA-induced cerebrovascular perturbations, and 
represents a possible link between DKA mediated inflammation and DKA 
cerebrovascular crises.  
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CHAPTER 3: ELEVATED LEUKOCYTE AZUROPHILIC ENZYMES IN 
HUMAN DIABETIC KETOACIDOSIS PLASMA DEGRADE 
CEREBROVASCULAR ENDOTHELIAL JUNCTIONAL PROTEINS 
  
74 
 
 
 
3.1 Introduction 
Type 1 diabetes mellitus (T1DM) is a chronic affliction that occurs primarily in 
children, whose diagnosis has been occurring at an increasingly younger age (1, 2). A 
serious complication of T1DM is diabetic ketoacidosis (DKA), which results from severe 
insulin deficiency. DKA refers to the triad of metabolic acidosis, hyperglycemia and 
ketonemia (3). Intracranial cerebrovascular complications such as stroke (4), hemorrhage 
(5, 6) and cerebral edema (7, 8) have all been shown to be associated with DKA in 
children. Previous work in our lab has shown that DKA is associated with a systemic 
inflammatory response that stimulates polymorphonuclear neutrophil (PMN) adherence to 
the brain microvascular endothelium via CXCL-1/CXCL-8 (9, 10).  
PMN antimicrobial/proteolytic enzymes are normally stored safely in azurophilic 
granules (11). Upon inflammatory stimulation, PMN undergo degranulation and granules 
containing azurophilic enzymes (e.g., leukocyte elastase [HLE], proteinase-3 [PR-3], 
cathepsin G [CTSG] and myeloperoxidase [MPO]) are released by activated circulating 
or adherent PMNs. Elevated azurophilic enzymes produced by adherent PMNs may 
contribute to degradation of the vascular element and potentially contribute to 
destabilization of the BBB (12, 13). 
We hypothesized that DKA is associated with elevated PMN azurophilic enzymes 
and that some or all of these enzymes may lead to BBB dysfunction. Thus, our aims using 
human DKA blood were: (1) to measure plasma levels of PMN azurophilic enzymes, (2) 
to determine any relationships between enzyme levels and DKA severity and (3) to 
determine the consequential effects of enzyme levels on cerebrovascular endothelial 
junctional proteins in vitro. 
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3.2 Methods 
 This study was approved by the Health Sciences Research Ethics Board at 
Western University. Patients were recruited at our regional tertiary care centre; the 
Children’s Hospital, London Health Sciences Centre (London, ON). 
3.2.1 Human Subjects 
Consent was obtained from the legal guardians of all pediatric patients admitted 
with DKA, and both legal guardian consent and patient assent were obtained for type-1 
diabetes control patients. Biochemical diagnostic criteria for DKA include hyperglycemia 
> 11 mmol/L, bicarbonate < 15 mmol/L and ketonurea (14). DKA is classed according to 
severity of acidosis as mild DKA (venous pH < 7.3), moderate DKA (pH < 7.2) or severe 
DKA (pH < 7.1) (15, 16). A majority of DKA cases used in this study were severe. Clinic 
patients with insulin controlled type-1 diabetes (HbA1c < 10% and no DKA for at least 3 
months) served as controls (CON). 
3.2.2 Blood Collection and Processing 
Blood for research purposes was obtained on hospital presentation at the time of 
clinically-indicated blood draws. Blood was drawn into citrate-containing tubes 
(Vacutainers
®
, BD Biosciences, Mississauga, ON) by certified nursing personnel, placed 
on ice, and immediately transferred to the Translational Research Centre facility for 
processing by standard operating procedures (www.translationalresearch.ca, London, 
ON) (17, 18). Briefly, blood was centrifuged at 1500 g for 15 min (4
o
C), and the upper 
plasma layer was collected in 250 µl aliquots and frozen at −80 °C. Thawed plasma was 
maintained on ice for short periods prior to use in experiments and freeze-thaw cycles 
were avoided. 
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3.2.3 Polymorphonuclear Neutrophil Enzyme Measurement 
 The plasma concentrations of several major PMN-associated enzymes were 
measured via enzyme-linked immunosorbent assay (ELISA) in patients. We measured the 
plasma concentration of the serine proteases human leukocyte elastase (HLE; 1:100 
dilution; Abcam, Cambridge, UK), proteinase-3 (PR-3; 1:30 dilution; Cloud-Clone Corp., 
Houston, TX) and cathepsin G (CTSG; undiluted; MyBioSource, Inc., San Diego, CA). 
The plasma concentration of myeloperoxidase (MPO; 1:1 dilution; Abcam) as a marker of 
PMN activation was also assessed. Concentrations were adjusted for dilution factor. 
3.2.4 Cell Culture 
 Primary human brain endothelial primary cells (hBMEC) were kindly provided by 
Dr. Mahmud Bani (NRC, Ottawa, ON) and used as a model of brain microvascular 
endothelium in vitro. hBMEC were cultured in EBM-2 Endothelial Growth Basal 
Medium (Clonetics®; Lonza) supplemented with Clonetics® EGM®-2 MV SingleQuots 
kit (Lonza), 1% GA-1000 (Lonza) on gelatin (0.5% w/v in water; Sigma-Aldrich) coated 
plates. The cells were maintained at 37°C in a humidified atmosphere with 5% CO2 and 
reseeded when the cell monolayer became sub-confluent. hBMEC at passage 2-15 were 
used in all experiments. For treatments, hBMEC were seeded into 24-well plates (8.0×10
5 
cells/well) and grown until confluence. 
3.2.5 In vitro Experimental Approach 
 hBMEC monolayers were treated with human neutrophil PR-3 (Athens Research 
& Technology, GA), HLE (Abcam) and MPO (Abcam) diluted in serum-free VascuLife® 
basal medium (VL; Lifeline Cell Technology). Growth media was aspirated and wells 
were treated with basal medium only (-), HLE (2 µg/mL) (19), PR-3 (5 µg/mL) (20, 21) 
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or MPO (35 ng/mL) (22) by themselves or all in combination (Total) for 1 hour at 37°C 
(5% CO2). MPO-treated wells (MPO and Total) were supplemented with 80 µM H2O2 to 
provide a substrate for free radical generation. 
3.2.6 Immunoblotting 
Degradation of zonula occludens-1 (ZO-1) and β-catenin were assessed using 
immunoblotting. Following protease treatment, wells were washed 3 times with ice-cold 
phosphate buffered saline (PBS) then lysed in 200µL of hot SDS-electrophoresis sample 
buffer. Samples were then stored at -20°C. Prior to running, samples were boiled for 5 
minutes then electrophoresed with 10% SDS-polyacrylamide gel electrophoresis. Proteins 
were transferred overnight to a BioTrace polyvinylidene diflouride (PVDF) membrane 
(Pall Corporation, Port Washington, NY). Following transfer, the membranes were 
blocked in 5% skim milk in 0.1% Tween tris-buffered saline (TBST) for 1 hour at room 
temperature. Membranes were then incubated with primary antibody, polyclonal rabbit 
anti-ZO-1 (mid) 1:2000 (Invitrogen, Carlsbad, CA) or polyclonal rabbit anti-β-catenin 
1:4000 (Abcam, Cambridge, UK) in 2% skim milk in tris-buffered saline (TBS) for 2 
hours at room temperature. The membrane was then washed 3 times for 5 min each with 
TBST then incubated with secondary horseradish peroxidase-conjugated antibody, goat 
anti-rabbit (Invitrogen) in 2% skim milk in TBS for 1 hour at room temperature. Finally, 
membranes were washed for 5 min twice and then 10 min with TBS. For a loading 
control, each membrane was also probed with monoclonal anti-lamin-β1 (Abcam). Bound 
target antibodies were visualized using enhanced chemiluminescence detection (2.5mM 
Luminol, 0.4mM p-coumaric acid, 0.02% H2O2 in 100mM Tris buffer; Sigma-Aldrich). 
Images of the immunoblots were captured using a MicroChemi imaging system 
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(Froggabio) and band quantification was done with GelQuant Pro Software (Froggabio). 
Target bands were quantified as an optical density (O.D.) ratio to its corresponding lamin-
β1 band. 
3.2.7 Quantification of Monolayer Detachment 
 To determine whether there was significant hBMEC detachment following PMN 
enzyme treatment, we quantified the number of cells present in the culture media 
following treatment. hBMEC were grown on gelatin-coated 24-well plates until the 
monolayer reached confluency. Cells were treated for 1 hour at 37°C with PMN enzymes. 
Subsequently, the culture media from wells were collected into microtubes. Samples were 
centrifuged at 20,000 g for 10 minutes, supernatant discarded and pellets were 
resuspended in cold 0.4% Trypan Blue in PBS. Cells were resuspended in a much smaller 
volume (10X concentrated) relative to the original sample volume to allow for a more 
accurate cell counting. The number of cells in each sample was counted using a 
Haemocytometer (Hausser Scientific, Horsham, PA) and expressed as the number of cells 
detached per well.  
3.2.8 Statistical Analysis 
Data was screened for normality and assessed with either the Mann-Whitney U 
test (nonparametric data) or the Student’s t-test (parametric data). For multiple 
comparisons, the Kruskal-Wallace test with post-hoc Tukey test (nonparametric data) or a 
One-Way Analysis of Variance (ANOVA) test with post-hoc Holm-Sidak test (parametric 
data) was used. Correlation analysis utilized the Spearman’s rank correlation coefficient. 
All data is presented as mean ± SEM, statistical significance (P < 0.05). 
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3.3 Results 
Study patients 
Plasma was obtained from type-1 diabetes patients either in acute DKA or an 
insulin-controlled state (CON). The two groups were age- and sex-matched (Table 3-1; 
n= 16 patients/group). Patients with DKA had significantly higher HbA1C values, 
compared to those with controlled type-1 diabetes (P < 0.001), indicating elevated blood 
glucose over the previous three months. DKA patients all had elevated blood glucose 
(27.4 ± 8.3 mmol/L) and metabolic acidosis on blood gas measurements (pH 7.00 ± 0.03; 
PCO2 20.8 ± 2.3 mmHg; HCO3
-
 5.9 ± 0.8 mmol/L; lactate 2.9 ± 0.7 mmol/L).  
DKA patients had an elevated complete blood leukocyte count (Table 3-2; n= 16) 
relative to age-specific normal ranges. Specifically, all DKA patients had neutrophilia and 
monocytosis (n= 14; Two patients did not have a differential WBC count done).  
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TABLE 3-1. Human Clinical and Biochemical Data for Type-1 Diabetes 
Patients  
Insulin Controlled (CON) or with Acute Diabetic Ketoacidosis (DKA). (n= 
16/group) 
 
CON DKA P value 
Mean age (years) 11.4 ± 1.0 11.7 ± 0.8 0.83 
Male: female ratio 8:8 8:8 1.00 
HbA1c (%) 8.3 ± 0.3 11.7 ± 0.5 < 0.001 
pH N/A 7.00 ± 0.03 
 
HCO3
- 
(mmol/L) N/A 5.9 ± 0.8 
 
pCO2 ( mmHg) N/A 20.8 ± 2.3 
 
Lactate (mmol/L) N/A 2.9 ± 0.7 
 
Blood glucose (mmol/L) N/A 27.4 ± 8.3 
 
Data presented as mean ± SEM. 
a; Boldface indicates significant P value (P < 0.05). N/A; data not gathered 
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TABLE 3-2. Differential White Blood Cell Count for DKA Patients 
 Cell type n= 16 
Healthy 
Reference Range 
Status 
Leukocytes, total (x10
9
/L) 22.99 ± 2.16 4.0-10 Elevated 
Neutrophils (x10
9
/L) 18.43 ± 1.96 4.0-5.3 Elevated 
Lymphocytes 
(x10
9
/L) 2.04 ± 0.17 1.4-4.0 Normal 
Monocytes (x10
9
/L) 1.54 ± 0.19 0.2-0.8 Elevated 
Eosinophils (x10
9
/L) 0.02 ± 0.01 0.0-0.8 Normal  
Basophils (x10
9
/L) 0.11 ± 0.01 0.0-0.1 Normal 
Data presented as mean ± SEM. 
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Polymorphonuclear neutrophil enzyme measurements 
 In order to assess PMN degranulation, plasma levels of the major azurophilic 
granule enzymes were investigated. The concentration of HLE, PR-3, CTSG and MPO 
was measured in DKA and CON plasma. It was found that HLE was significantly 
increased in DKA plasma (85.99 ng/mL) compared to CON plasma (31.61 ng/mL; P < 
0.001; Figure 3-1A). PR-3 was significantly increased in DKA plasma (27.04 ng/mL) 
compared to CON plasma (8.87 ng/mL; P < 0.001; Figure 3-1B). CTSG was assessed but 
found to be not significantly changed between CON and DKA plasma (P=0.81; Figure 3-
1C). MPO, a major component of the PMN oxygen-dependent antimicrobial pathway, 
was significantly increased in DKA plasma (5.49 ng/mL) compared to CON plasma (3.25 
ng/mL) (P < 0.001; Figure 3-1D). 
 
 
 
 
 
 
 
 
 
83 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3-1. Plasma Leukocyte Azurophilic Enzymes in DKA. DKA plasma was 
associated with increased circulating PMN enzymes. Circulating HLE increased in DKA 
plasma compared to CON plasma (A). The average concentrations in CON and DKA 
plasma were 31.6 ng/mL and 85.99 ng/mL, respectively. PR-3 was also increased 
significantly in DKA plasma compared to CON plasma (B). The average concentrations 
for CON and DKA were 8.87 ng/mL and 27.04 ng/mL, respectively. CTSG was not 
significantly changed between CON and DKA groups (C). Finally, MPO increased in 
DKA plasma compared to CON (D). Observed concentrations were 5.49 ng/mL and 3.25 
ng/mL, respectively. N.S. not significant; **P < 0.01; ***P < 0.001; n= 14 per group (A); 
n= 15 per group (B); n= 16 per group (C, D). 
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PR-3 was inversely correlated with blood pH 
In order to determine the relationship between level of significantly altered plasma 
PMN azurophilic enzymes in DKA samples and disease severity, correlation analysis was 
applied to data points graphed as concentration versus blood pH which was used as a 
surrogate of DKA severity. Plasma PR-3 (Figure 3-2B) concentration in DKA was found 
to be significantly inversely correlated with blood pH (rs = 0.73, P < 0.01). In contrast, no 
correlation could be detected for HLE (Figure 3-2A) or MPO (Figure 3-2C) (rs= -0.24, P= 
0.41 and rs= 0.06, P= 0.82, respectively). 
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FIGURE 3-2. Plasma PMN Azurophilic Enzyme Correlation with pH in DKA.  
PR-3 was significantly correlated with disease severity. Correlation analysis was applied 
to the concentration of the 3 significantly increased PMN azurophilic enzymes, HLE, PR-
3 and MPO in DKA plasma with blood pH. Only PR-3 concentration displayed 
significant inverse correlation with blood pH (rs= -0.7317, P= 0.002, n= 15) (B). Both 
HLE (rs= -0.24, P= 0.41, n= 14) (A) and MPO (rs= 0.06, P= 0.82, n= 16) (C) were not 
significantly correlated with blood pH. A line of best fit was added to the graphs to aid in 
interpretation of the data points. 
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PMN enzymes disrupt ZO-1 and β-catenin in vitro 
 Elevated PMN enzymes were applied to hBMEC monolayers in order to assess 
their effect on protein junctions. Specifically, we investigated degradation of both ZO-1 
and β-catenin, critical structural elements of TJs and AJs, respectively. PR-3 and total 
enzyme mixture both significantly decreased ZO-1 expression (Figure 3-3A, B; P < 0.05, 
P <0.01, respectively). No changes were seen in regards to ZO-1 degradation products. 
PR-3 and total enzyme mixture also both significantly increased the appearance of 
smaller molecular weight β-catenin degradation products (Figure 3-3C, D; P < 0.01 and P 
< 0.001, respectively). No significant changes were seen with regard to full length β-
catenin. H2O2 by itself as a control did not have an effect on either ZO-1 or β-catenin, full 
length or degradation (Data not shown). The changes in protein levels were not due to cell 
detachment from the monolayer as there were no changes in the number of detached cells 
in treatment media following treatment (P= 0.60; n= 3; Data not shown). 
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FIGURE 3-3. Enzyme-Mediated Degradation of ZO-1 and β-Catenin. An enzyme 
cocktail mixture consisting of HLE, PR-3 and MPO was able to degrade β-catenin. 
hBMEC monolayers were treated with a combination of significantly elevated PMN 
azurophilic enzymes; (-), basal media only; HLE, 2 µg/mL HLE; PR-3, 5 µg/mL PR-3; 
MPO, 35 ng/mL MPO + 80 µM H2O2; Total, 2 µg/mL HLE + 5 µg/mL PR-3 + 35 ng/mL 
MPO + 80 µM H2O2. Representative blots for ZO-1 and β-catenin are shown in (A) and 
(C), respectively. Full length ZO-1 expression (B) was significantly decreased by PR-3 
treatment and total enzyme treatment whereas full length β-catenin (D) was not 
significantly altered. No significant ZO-1 degradation products were observed (B). Total 
enzyme mixture and PR-3 treatment resulted in an increase of a range of smaller 
molecular weight β-catenin degradation bands (D). *P < 0.05, **P < 0.01, ***P < 0.001; 
n= 7-8. 
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3.4 Discussion 
In this present study, we report that DKA is associated with elevated neutrophils 
and induces increased PMN degranulation. While HLE, PR-3 and MPO were all elevated 
in DKA plasma, only PR-3 was positively correlated with DKA severity. PR-3 alone, or 
in combination with the other PMN enzymes, resulted in decreased expression of the tight 
junction protein ZO-1 and degradation of the adherens junction protein β-catenin in vitro. 
To our knowledge, this study is the first to employ human DKA tissues in relation to 
pathological changes in systemic PMN azurophilic enzymes.  
In this study, the differential white blood cell count of DKA patients showed 
monocytosis and neutrophilia, consistent with previous reports of  increased circulation of 
leukocytes during DKA (23, 24). Also, we show that PMN in acute DKA patients 
undergo degranulation with the release of azurophilic granule-specific enzymes, HLE, 
PR-3 and MPO. Ubiquitous PMN activation in DKA patients is in direct agreement with 
our previous work that showed increased PMN-endothelial adherence due to the 
cytokines CXCL-1 and CXCL-8 (10) as well as DKA-induced regulation of leukocyte-
derived MMPs (Chapter 2).  
The increased circulating enzymes, HLE, PR-3 and MPO, are relevant to 
intracerebral complications as there is evidence linking them to endothelial perturbation 
(25-28). HLE can disrupt junctional proteins such as E-cadherin (19, 25, 29) and β-
catenin (30) and break down components of the extracellular matrix (31, 32). HLE has 
also been shown to facilitate PMN transmigration, thereby contributing to endothelial 
disruption indirectly (33). HLE can also activate MMP-9 (34, 35), thus potentiating the 
destructive effects of the MMPs that we have shown to be elevated in DKA plasma 
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(Chapter 2). The presence of extracellular PMN enzymes may also affect endothelial 
stability indirectly; HLE has also been shown to induce CXCL-8 expression (36, 37) 
which has been shown to facilitate PMN adherence to the endothelium in DKA (10). 
PR-3 is also involved in PMN transmigration (38), and MMP activation (35). PR-
3 has been shown to potentiate the effects of CXCL-8 by cleavage into a more potent 
form (39). Only PR-3 was positively correlated with DKA severity. This latter finding 
may be due to PMN activation by acidic extracellular pH as it has been shown that a sub 
fraction of PMN PR-3 localizes not to azurophilic granules but to secretory vesicles (40, 
41). Secretory vesicles are the first vesicles to be released by PMN following stimulation 
and tend to be released in a dose-dependent manner (42). These vesicles are released 
faster than azurophilic granules and so it is conceivable that only PR-3, at this stage in 
DKA progression, is released in a pH-dependent manner 
Through its ability to generate hypohalous acid, MPO can facilitate endothelial 
dysfunction, both in vitro and in vivo (22, 28, 43), as well as degrade the endothelial 
extracellular matrix (26). Hypochlorous acid generated by MPO can activate MMP-9 
(44), and MMP-9 was elevated in DKA (Chapter 2). Apart from its oxidative compound-
generating ability, MPO facilitates leukocyte activation and adhesion to the endothelium 
during inflammation (45, 46). 
In support of the notion that PMN azurophilic enzymes contribute to vascular 
dysfunction in DKA, a total enzyme cocktail containing significantly increased 
azurophilic enzymes, HLE, PR-3 and MPO decreased ZO-1 expression in brain 
microvascular endothelial cells in vitro. ZO-1 is an integral component of the tight 
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junction as it anchors both occludin and claudin to the actin cytoskeleton and is important 
for junctional regulation (47). Reduced expression of ZO-1 facilitates endothelial 
permeability (48-50).  
Our total enzyme cocktail also degraded β-catenin in human brain endothelial 
cells. β-catenin is one of the terminal cytoplasmic proteins in the adherens junction. Its 
role is to anchor the intercellular component VE-cadherin to the cytoskeleton and it is 
responsible for junctional regulation (51). β-catenin loss is associated with vascular 
instability and hemorrhage (52). However, we did not observe a significant decrease in 
full length β-catenin concurrently with appearance of the degradation products, indicating 
increased protein turnover as opposed to only protein breakdown. Also, since we did not 
observe any enzyme-mediated degradation products with ZO-1, this implies that β-
catenin and ZO-1 are differentially processed. These changes most likely occurred 
through extracellular-intracellular signalling as it has been shown that disruption of both 
the membrane-bound proteins occludin and VE-cadherin result in disruption of their 
cytosolic counterparts (53, 54). 
The concentrations of PMN enzymes used in our in vitro experiments were greater 
than what we measured in plasma. Physiologically, PMN degranulation occurs at the 
endothelial surface, or inside the intercellular compartment. In actuality, the 
concentrations at the endothelium of PMN-derived molecules are almost certainly greater 
than those that we measured in plasma. In fact, HLE (55, 56), lactoferrin and defensins 
(57) and cytokines (58) have been suggested to reach local concentrations of up to 2 
mg/ml, following PMN degranulation. The levels of enzymes we measured in plasma are 
most likely “spill over” from more localized domains and would be diluted as compared 
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to the effective concentrations at the level of the endothelium. Therefore, we used enzyme 
concentrations used in other publications (19-22) 
As neutral proteases, both HLE and PR-3 may display slightly reduced catalytic 
activity at acidic pH but as pH is normalized during DKA treatment, HLE and PR-3 
activity would increase (59, 60). Our observation that PR-3 release is correlated with a 
lower pH raises the possibility that increased PR-3 release under acidotic conditions may 
compensate for decreased catalytic activity. MPO is known to be more active under acidic 
conditions as well, thereby potentiating its ability to generate oxidative compounds in 
DKA patients prior to treatment (61).  
This study has several limitations. First, we assumed that HLE and PR-3 were of 
PMN origin due to their release concurrent with PMN-specific MPO. Other notable 
plasma sources of HLE and PR-3, however minor, include endothelial cells (62) and 
monocytes (63). Future studies should examine specific leukocyte components isolated 
from DKA patients. Second, the release and maximal effects of the individual enzymes, 
HLE, PR-3 and MPO during DKA and its treatment are currently unknown and require 
further examination. 
We have shown previously that pediatric DKA is associated with inflammation 
and PMN adherence to brain microvascular endothelial cells. We now demonstrate 
increased circulating PMN azurophilic enzymes (HLE, PR-3 and MPO) that reduced the 
expression of the tight junction protein, ZO-1 and degraded the adherens junction protein, 
β-catenin. These findings support the notion of DKA as an inflammatory condition and in 
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conjunction with our other work (10), implicates PMN activation and degranulation in 
DKA-associated BBB disruption.  
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4.1 Discussion  
DKA is associated with intracerebral vascular complications in children, such as 
stroke (1), hemorrhage (2) and cerebral edema (3). The mechanisms of these 
complications are not well known. 
DKA is an inflammatory condition involving increases in circulating cytokines 
such as CXCL-1 (GROα), CXCL-8 (IL-8), IL-6 and IFN-α2 (4). These cytokines are 
known to cause activation of leukocytes, including PMN (5). Thus, I hypothesized that 
during pediatric DKA, inflammation leads to widespread activation of leukocytes which 
then release destructive enzymes. This enzyme surge could be responsible for facilitating 
cerebrovascular damage. 
 In this thesis, we observed alterations in the plasma level of a number of MMPs 
and TIMP-4 as well as PMN azurophilic enzymes. DKA plasma was associated with 
decreased MMP-2 and increased MMP-8, MMP-9 and TIMP-4. DKA plasma was also 
associated with increased PMN azurophilic enzymes, HLE, PR-3 and MPO. Our findings 
are consistent with a widespread inflammatory condition occurring in DKA patients. 
HLE, PR-3 and MPO are major components of PMN azurophilic granules, which are 
only released upon degranulation following PMN activation (6). In fact, MPO is 
exclusively a component of the PMN azurophilic granules and as such is widely utilized 
as a marker for PMN activation. MMP-8 is found in the PMN secondary granules (7) and 
is released upon activation as well, albeit earlier in inflammation than the other PMN 
enzymes (8). Interestingly, active transcription of MMP-8 is thought to occur only in 
immature PMN, indicating mobilization from bone marrow of immature PMN during 
DKA: a hallmark of an overwhelming inflammatory response (6). MMP-9 is, among 
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other sources, associated with the PMN tertiary granule. Further support for notion of 
PMN-associated MMP-9 comes from the detection of lipocalin-associated MMP-9 
complex in DKA plasma, characteristic of PMN-associated MMP-9. 
 The plasma levels of MMP-8, MMP-9 and PR-3 were positively correlated with 
DKA severity. The aforementioned correlations are in agreement with studies that have 
shown that acidic pH directly stimulates release of MMPs from cells (9-11) and leads to 
enhanced PMN activation (12). The severity of acidosis during DKA has previously been 
shown to be determinant of the magnitude of consciousness impairment. Cerebral 
function in DKA patients with cerebral edema is closely tied to pH; a lower pH is 
correlated with increased level of cognitive impairment (13). Our data supports the 
notion that the relationship between pH and severity of DKA neurological impairment 
may involve pathological regulation of MMP-8 and MMP-9 as well as PR-3.  
 We have shown that DKA plasma is associated with increased levels of MMP-8, 
MMP-9, HLE, PR-3 and MPO. The presence of these enzymes at the level of the 
endothelium could potentially lead to breakdown of the intercellular junctions and 
facilitate fluid movement into the brain (e.g., vasogenic edema). Indeed, using human 
brain microvascular endothelial cells, we have shown a potential role for PR-3, HLE and 
MPO in disruption of both AJs and TJs. Numerous studies have implicated the MMPs 
and PMN azurophilic enzymes in facilitating breakdown of the BBB (14-17).  
 Our data raises the possibility of a 2-stage insult to the brain microvasculature. 
We have shown that DKA stimulates the release of MMP-8, MMP-9, HLE, PR-3 and 
MPO. Following DKA-induced release of these enzymes, MMP-8 and MPO can be 
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expected to display higher catalytic activity during the initial stages of DKA when blood 
pH is low (18, 19). During treatment and the ensuing normalization of pH, the catalytic 
activity of MMP-9 (20), HLE and PR-3 (21) can be expected to increase, potentially 
leading to a second wave of protease activity.  
 These studies have provided insight into the circulating protease profile occurring 
in pediatric DKA patients. Future studies could examine the effects on these enzymes in 
vivo by assessing markers of BBB disruption in DKA plasma. Solubilized junctional 
proteins in circulation like occludin, claudin-5 and cadherin might indicate cleavage and 
subsequent release from the brain endothelium. Unfortunately, due to the ethical 
ramifications of patient studies, it is difficult to probe more into the physiological 
functions. The effects of these enzymes on BBB structure and function could be assessed 
in vitro. Isolated PMN could be applied to human cerebromicrovascular endothelial 
monolayers under DKA conditions (e.g., acidosis, hyperglycemia, and DKA-specific 
cytokine mixture) in order to assess their direct effect on monolayer integrity. The effect 
of PMN on the BBB could be assessed in a juvenile mouse model of DKA as well (22). 
 
 
 
 
 
 
101 
 
 
 
 
  
FIGURE 4-1. Proposed Mechanism of PMN-Mediated DKA 
Endothelial Perturbations. DKA is a well-known inflammatory 
condition. Inflammatory cytokines in circulation serve to activate 
endothelial cells and PMN, recruiting them to the endothelial surface. 
PMN degranulate upon activation and the released proteases destroy 
the junctions between adjacent cells. Released proteases may also 
potentiate existing DKA-mediated cytokines, thereby facilitating a 
positive feedback mechanism. This results in the loss of vascular 
integrity, leading to fluid and solutes moving across the BBB, thus 
facilitating DKA-mediated cerebrovascular dysfunction. 
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